Page last updated: 2024-12-05

nortriptyline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nortriptyline is a tricyclic antidepressant (TCA) medication used to treat major depressive disorder and other conditions such as chronic pain, anxiety, and bedwetting. It is a tertiary amine derivative of amitriptyline. Nortriptyline is synthesized via a multi-step process that involves the reaction of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene with a substituted propylamine derivative. Nortriptyline acts by blocking the reuptake of serotonin and norepinephrine in the brain, thereby increasing their levels in the synaptic cleft. This mechanism leads to its antidepressant effects. Its importance lies in its efficacy in treating depression and other conditions. It is studied extensively for its pharmacological properties, therapeutic potential, and its potential to improve quality of life for patients with various conditions.'

Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4543
CHEMBL ID445
CHEBI ID7640
SCHEMBL ID34527
MeSH IDM0015002

Synonyms (172)

Synonym
BIDD:PXR0187
BRD-K91263825-003-03-2
gtpl2404
methyl({3-[(2e)-tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene]propyl})amine
(2)10,11-dihydro-n-methyl-5h-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine
sensaval
3-(5,6-dihydrodibenzo[[?],[?]][7]annulen-11-ylidene)-n-methyl-propan-1-amine
1-propanamine, 3-(10,11-dihydro-5h-dibenzo[a,d]cyclohepten-5-ylidene)-n-methyl-
DIVK1C_000151
KBIO1_000151
noritren
aventyl
nortriptylinum [inn-latin]
desitriptyline
10,11-dihydro-5-(3-methylaminopropylidene)-5h-dibenzo(a,d)(1,4)cycloheptene
nortryptiline
nortryptyline
5-(alpha-methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene
hsdb 3371
5h-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-n-methyl-
noramitriptyline
desmethylamitriptylin
nortriptyline [inn:ban]
amitryptyline, demethyl-
desitriptilina
1-propanamine, 3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-n-methyl-
ccris 9175
3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-n-methylpropylamine
nortriptilina [dcit]
demethylamitryptyline
brn 2216786
lumbeck
einecs 200-788-8
n-methyl-3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-yliden)propylamin
10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine
5-(3-(methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene
5-(3-methylaminopropylidene)-10,11-dihydro-5h-dibenzo(a,d)cycloheptene
SPECTRUM_001041
3-(10,11-dihydro-5h-dibenzo[a,d]cyclohepten-5-ylidene)-n-methyl-1-propanamine
lopac-n-7261
NCGC00014483-03
NCGC00014483-02
IDI1_000151
PRESTWICK3_000254
PDSP2_001788
LOPAC0_000868
NCGC00014483
BPBIO1_000076
PDSP1_001805
BSPBIO_002111
BSPBIO_000068
AB00052061
C07274
nortriptyline
72-69-5
10,11-dihydro-n-methyl-5h-dibenzo[a,d]cycloheptene-delta5,gamma-propylamine
DB00540
NCI169453 ,
nortriptylina
desmethylamitriptyline
CHEBI:7640 ,
10,11-dihydro-n-methyl-5h-dibenzo[a,d]cycloheptene-delta(5,gamma)-propylamine
demethylamitriptyline
3-(10,11-dihydro-5h-dibenzo[a,d][7]annulen-5-ylidene)-n-methylpropan-1-amine
ateben
avantyl
NCGC00024261-03
nortriptylinum
NCGC00024261-04
KBIOGR_000870
KBIOSS_001521
KBIO2_001521
KBIO2_004089
KBIO2_006657
KBIO3_001611
NCI60_001354
SPECTRUM4_000455
NCISTRUC2_000700
SPBIO_002287
SPECTRUM2_000997
NINDS_000151
SPBIO_001093
NCISTRUC1_000856
SPECTRUM3_000526
PRESTWICK1_000254
PRESTWICK0_000254
NCIOPEN2_004361
SPECTRUM1500442
SPECTRUM5_001377
QTL1_000063
PRESTWICK2_000254
NCGC00014483-04
NCGC00024261-06
NCGC00024261-05
HMS2091J20
NCGC00014483-11
nci-169453
sesaval
CHEMBL445
nsc-757234
nortriptyline (inn)
D08288
nortrilen (tn)
HMS500H13
HMS1920B20
nortriptilina
unii-bl03sy4lxb
nsc 757234
bl03sy4lxb ,
pharmakon1600-01500442
nsc757234
ksc-315-028-
KUC112478N
CCG-38266
NCGC00014483-10
NCGC00014483-12
NCGC00014483-07
NCGC00014483-05
NCGC00014483-08
NCGC00014483-09
NCGC00014483-06
demethylamitriptylene
methyl({3-[(2e)-tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene]propyl})amine
us8629135, sw-02
bdbm112777
21B ,
10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-d(sup5,.gamma.)-propylamine
nortriptyline [inn]
nortriptyline [mi]
nortriptyline [vandf]
amitriptyline hydrochloride impurity c [ep impurity]
nortriptyline [who-dd]
3-(10,11-dihydro-5h-dibenzo(a,d)(7)annulen-5-ylidene)-n-methylpropan-1-amine
SCHEMBL34527
psychostyl (salt/mix)
10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptane-.delta.,.gamma.-propylamine
5-[3-(methylamino)propylidene]dibenzo[a,e]cyclohepta[1,5]diene
10,11-dihydro-5-(3-methylaminopropylidene)-5h-dibenzo[a,d][1,4]cycloheptene
5h-dibenzo[a,d]cycloheptene-.delta.5,.gamma.-propylamine, 10,11-dihydro-n-methyl-
PHVGLTMQBUFIQQ-UHFFFAOYSA-N
3-(10,11-dihydro-5h-dibenzo[a,d]cyclohepten-5-ylidene)-n-methylpropylamine
AB00052061_16
DTXSID9023384 ,
triptyline-m nor
SR-01000000223-4
MRF-0000480
SBI-0050843.P004
'3-(10,11-dihydro-5h-dibenzo[a,d][7]annulen-5-ylidene)-n-methylpropan-1-amine'
Q61387
aventyl;desitriptilina
SDCCGSBI-0050843.P006
NCGC00014483-23
NCGC00014483-16
n-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
F82279
MS-23718
NCGC00014483-14
HY-118620
CS-0067638
EN300-57709
methyl(3-{tricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine
n06aa10
3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-n-methyl-1-propanamine
3-(10,11-dihydro-5h-dibenzo
10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-d(sup5,gamma)-propylamine
nortiptylinum (inn-latin)
dtxcid903384
5h-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine, 10,11-dihydro-n-methyl
10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-delta5,gamma-propylamine
nortriptylinum (inn-latin)
demethylamitryptylene
lambeck

Research Excerpts

Overview

Nortriptyline (NTP) is a selective serotonin-norepinephrine reuptake inhibitor antidepressant. It is widely used in clinics and found in environmental water matrices. It has a Cu,b that is 2-fold below its IC50, which is comparable to the nAChR antagonist (±)-mecamylamine.

ExcerptReferenceRelevance
"Nortriptyline (NTP) is a selective serotonin-norepinephrine reuptake inhibitor antidepressant, widely used in clinics and found in environmental water matrices."( Exposure to tricyclic antidepressant nortriptyline affects early-life stages of zebrafish (Danio rerio).
Andrade, TS; Camargo, NS; Domingues, I; Fascineli, ML; Grisolia, CK; Oliveira, AC; Oliveira, R; Sousa-Moura, D; Villacis, RAR, 2021
)
1.62
"Nortriptyline is an exception with a Cu,b that is 2-fold below its IC50, which is comparable to the nAChR antagonist (±)-mecamylamine, for which Cu,b is 4-fold below its IC50; both drugs will inhibit a substantial fraction of α4β2 nAChRs."( Therapeutic doses of antidepressants are projected not to inhibit human α4β2 nicotinic acetylcholine receptors.
Cremers, T; Flik, G; Hofland, CM; Hurst, RS; Rollema, H; Shaffer, CL; Weber, ML, 2013
)
1.11
"Nortriptyline is a NET-selective tricyclic antidepressant (TCAs) that has been widely used for the treatment of depression."( Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[¹⁸F]FMeNER-D₂.
Arakawa, R; Fujiwara, H; Ito, H; Kato, M; Kawamura, K; Kimura, Y; Kodaka, F; Murakami, Y; Nagashima, T; Nogami, T; Okubo, Y; Shimada, H; Suhara, T; Suzuki, M; Takahashi, H; Takahata, K; Takano, H; Tateno, A; Yamada, M; Zhang, MR, 2014
)
1.39
"Nortriptyline is a readily-available, cheap and comparatively well-tolerated tricyclic antidepressant."( Nortriptyline in knee osteoarthritis (NortIKA Study): study protocol for a randomised controlled trial.
Alchin, JS; Hooper, GJ; Hudson, B; Mangin, D; Stamp, LK; Thompson, BF; Toop, L; Williman, JA, 2015
)
2.58
"Nortriptyline is an efficacious aid to smoking cessation with a magnitude of effect similar to that for bupropion and nicotine replacement therapies."( Nortriptyline for smoking cessation: a review.
Hughes, JR; Lancaster, T; Stead, LF, 2005
)
2.49
"Nortriptyline is a promising adjunct for smoking cessation. "( Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking.
Frederick, S; Hall, SM; Hartz, DT; Humfleet, G; Muñoz, RF; Reus, VI; Sees, KL; Triffleman, E, 1998
)
3.19
"Nortriptyline is a preferential noradrenaline uptake inhibitor, while the dimethylated compound, chlorimipramine also has a profound influence on serotonin neurons."( Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects.
Asberg, M, 1976
)
0.98
"For nortriptyline there is an inverse ratio, with more nortriptyline and desmethylnortriptyline in the older animals than in the young ones."( [Proceedings: Age and sex specificity of organ distribution and metabolism of chlorprothixene and nortriptyline in the rat (author's transl)].
Dell, HD; Fassbender, W; Kamp, R; Lorenz, D, 1976
)
0.95
"Nortriptyline is an effective antiarrhythmic agent which may be given twice a day even in patients with impaired ventricular function."( The antiarrhythmic effect of nortriptyline in cardiac patients with ventricular premature depolarizations.
Barnard, T; Bigger, JT; Giardina, EG; Johnson, L; Louie, M; Saroff, AL, 1986
)
1.28
"Nortriptyline hydrochloride is an effective antidepressant that, in depressed patients without heart disease, causes significantly less orthostatic hypotension than imipramine."( Nortriptyline in depressed patients with left ventricular impairment.
Bigger, JT; Giardina, EG; Glassman, AH; Johnson, LL; Roose, SP; Walsh, BT; Woodring, S, 1986
)
2.44

Effects

Nortriptyline has the potential for serious side-effects, but none have been seen in the few small trials for smoking cessation. There was no evidence of a significant effect for selective serotonin reuptake inhibitors on their own (RR 0.93, 95% CI 0.71 to 1.22)

ExcerptReferenceRelevance
"Nortriptyline has the potential for serious side-effects, but none have been seen in the few small trials for smoking cessation.There was no evidence of a significant effect for selective serotonin reuptake inhibitors on their own (RR 0.93, 95% CI 0.71 to 1.22, N = 1594; 2 trials fluoxetine, 1 paroxetine, 1 sertraline) or as an adjunct to NRT (3 trials of fluoxetine, N = 466, RR 0.70, 95% CI 0.64 to 1.82)."( Antidepressants for smoking cessation.
Cahill, K; Hartmann-Boyce, J; Hughes, JR; Lancaster, T; Stead, LF, 2014
)
1.12
"Nortriptyline and clonidine have been used in patients who do not tolerate first-line agents."( Current treatment options in smoking cessation.
Bhat, A; Crain, D, 2010
)
1.08
"Nortriptyline has been reported to be safe in porphyric patients."( Exacerbation of acute intermittent porphyria by nortriptyline.
Krummel, SJ; Wesner, RB, 1986
)
1.25

Actions

Nortriptyline promotes cell acidification and suppresses macropinocytosis. The increase in impedance was reduced by 29% after ADP induction (p=0.046)

ExcerptReferenceRelevance
"Nortriptyline promotes cell acidification and suppresses macropinocytosis, providing a link between fatty acid uptake and tumor progression."( Stopping the fat: Repurposing an antidepressant for cancer treatment.
Bhullar, D; Commisso, C, 2023
)
1.63
"With nortriptyline the increase in impedance was reduced by 29% after ADP induction (p=0.046)."( Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline.
Bauriedel, G; Flöck, A; Hammerstingl, C; Höfels, S; Maier, W; Nickenig, G; Schuhmacher, A; Skowasch, D; Tuleta, I; Zobel, A, 2010
)
1.03

Treatment

Nortriptyline treatment was associated with a significantly higher rate of serious adverse cardiac events compared with paroxetine. Treatment was accompanied by marked improvements in anxiety, certain respiratory symptoms, and overall physical comfort. placebo effects were negligible.

ExcerptReferenceRelevance
"Nortriptyline treatment seems to be a useful alternative."( Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease.
Huibers, MJ; Knipschild, PG; van Schayck, CP; Wagena, EJ; Wouters, EF, 2005
)
1.35
"Nortriptyline treatment did not influence serum hormone levels."( Nortriptyline and pituitary-thyroid function in affective disorder.
Nordgren, L; von Schéele, C, 1981
)
2.43
"Nortriptyline-treated patients had statistically significant heart rate increases at each assessment as determined by RR intervals on electrocardiogram (14.5-18 bpm)."( The cardiovascular effects of bupropion and nortriptyline in depressed outpatients.
Batey, SR; Holloman, LC; Johnston, JA; Kiev, A; Masco, HL; Wenger, TL, 1994
)
1.27
"Nortriptyline treatment was initiated with a 75- to 125-mg dose depending on weight in 26 depressed inpatients in an open-label study."( High initial nortriptyline doses in the treatment of depression.
Griffin, M; Peabody, CA; Warner, MD, 1993
)
2.1
"Nortriptyline treatment was associated with a significantly higher rate of serious adverse cardiac events compared with paroxetine."( Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
Bigger, JT; Finkel, MS; Gaffney, A; Gergel, I; Kennedy, JS; Laghrissi-Thode, F; McCafferty, J; Narayan, M; Nelson, JC; Pollock, BG; Roose, SP, 1998
)
1.31
"Nortriptyline-treated patients on a mean dose of 117 mg/day had a mean nortriptyline level of 141 ng/ml."( A comparison study of amitriptyline and nortriptyline with plasma levels.
Biggs, JT; Clayton, PJ; Ziegler, VE, 1977
)
1.25
"Nortriptyline treatment was accompanied by marked improvements in anxiety, certain respiratory symptoms, overall physical comfort, and day-to-day function; placebo effects were negligible."( Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease.
Borson, S; Deffebach, M; Gayle, T; Lakshminarayan, S; McDonald, GJ; VanTuinen, C, 1992
)
1.25
"In nortriptyline-treated patients (N = 10, excluding one outlier), PSOP was significantly correlated with percent change in Hamilton ratings (rho = -0.55, p less than 0.05); a similar association was also found in the subsample of electroconvulsive therapy-treated patients (N = 6, rho = -0.77, p less than 0.05)."( Pretreatment systolic orthostatic blood pressure (PSOP) and treatment response in elderly depressed inpatients.
Hoch, CC; Houck, PR; Kupfer, DJ; Perel, JM; Reynolds, CF; Stack, JA, 1988
)
0.79
"In nortriptyline-treated dogs, however, nortriptyline itself produced an increase in VFT which was reversed by bretylium, and VFT after bretylium was not significantly elevated until 90 min to a value of 25.2 +/- 9.6 mA (control: 5.2 +/- 0.9 mA)."( Antifibrillatory action of bretylium: role of the sympathetic nervous system.
Kopia, GA; Lucchesi, BR, 1987
)
0.79
"The nortriptyline-treated subjects with a PSOP of greater than or equal to 10 mm Hg had a greater improvement than those with a PSOP of less than 10 mm HG (t = -2.36, p less than 0.05)."( Pretreatment orthostatic hypotension as a predictor of response to nortriptyline in geriatric depression.
Bender, M; Schneider, LS; Sloane, RB; Staples, FR, 1986
)
0.99
"Nortriptyline pretreatment did not modify either the uptake, subcellular distribution, or the metabolism of (3)H-noradrenaline injected into the lateral cerebral ventricles.4."( The reversal of the central effects of noradrenaline by antidepressant drugs in mice.
Cowell, P; Davey, MJ, 1968
)
0.97
"The treatment with nortriptyline and venlafaxine (both at 30 mg/kg, intraperitoneally) blocked dexamethasone-induced increase in the immobility time and the latency to self-care."( Venlafaxine and nortriptyline reverse acute dexamethasone-induced depressive-like behaviors in male and female mice.
Cagni, FC; Costa, LRF; de Souza, IBMB; Gavioli, EC; Lima, RH; Silva Junior, ED; Tiago, PRF, 2019
)
1.18
"Treatment with nortriptyline enhanced the efficacy and reduced the cognitive adverse effects of ECT relative to placebo. "( Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects.
Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009
)
0.71
"Treatment with nortriptyline alone was not effective."( A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine.
Aquino, CC; Domingues, RB; Domingues, SA; Kuster, GW; Silva, AL, 2009
)
0.92
"Pretreatment with nortriptyline inhibited pAkt induced by CSE and H(2)O(2) as well as restored HDAC activity that had been decreased by H(2)O(2) and CSE."( Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-δ.
Barnes, PJ; Ito, K; Mercado, N; To, Y, 2011
)
2.14

Toxicity

Nortriptyline group scored a significantly higher incidence of adverse events such as dysarthria or orthostatic dizziness, as well as increased heart rate.

ExcerptReferenceRelevance
" NT was less toxic than its parent compound, AT."( Protective effect of flavonoids on drug-induced hepatotoxicity in vitro.
Acosta, D; Davila, JC; Lenherr, A, 1989
)
0.28
"Tricyclic antidepressants (TCA) are drugs with Type IA antiarrhythmic properties that cause severe cardiac conduction blocks, hypotension, and ventricular dysrhythmias at toxic levels."( Phenytoin prophylaxis of cardiotoxicity in experimental amitriptyline poisoning.
Callaham, M; Pentel, P; Schumaker, H, 1988
)
0.27
" Preliminary studies indicate that adverse effects could be linked to polymorphisms of drug-metabolizing enzymes, but information on their clinical impact remains scanty and includes mainly case reports."( Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
Bachofer, J; Kissling, W; Leucht, S; Messner, B; Pfeiffer, H; Popp, J; Steimer, W; von Amelunxen, S; Zöpf, K, 2005
)
0.33
" Blood samples for concentration monitoring of amitriptyline and nortriptyline were taken weekly until discharge along with evaluations of depression (Hamilton Depression Scale and Clinical Global Impression Scale) and side effect (Dosage Record and Treatment Emergent Symptoms Scale; DOTES) scores."( Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
Bachofer, J; Kissling, W; Leucht, S; Messner, B; Pfeiffer, H; Popp, J; Steimer, W; von Amelunxen, S; Zöpf, K, 2005
)
0.57
" The efficacy was assessed using the 17-item Hamilton Rating Scale for Depression (HAM-D), Clinical Global Impression Scale (CGI) severity and improvement scores, while the safety profiles were assessed using the UKU Side Effect Rating Scale at baseline, and on days 7, 14, 28 and 56."( A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Akimoto, Y; Aoyama, H; Kamijima, K; Koda, R; Mimura, M; Nakagome, K; Otsubo, T; Tanaka, K; Yamada, H, 2005
)
0.56
" As for the safety profiles, the nortriptyline group scored a significantly higher incidence of adverse events such as dysarthria or orthostatic dizziness, as well as increased heart rate."( A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Akimoto, Y; Aoyama, H; Kamijima, K; Koda, R; Mimura, M; Nakagome, K; Otsubo, T; Tanaka, K; Yamada, H, 2005
)
0.84
" This review focuses on the tolerability, occurrence of adverse events, precautions required to prevent severe adverse events, and essential pharmacological interaction in the treatment of ADHD symptoms by non-stimulants."( The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.
Banaschewski, T; Heise, CA; Himpel, S; Rothenberger, A, 2005
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The tested drugs were very toxic to the protozoan Spirostomum ambiguum and the crustacean Thamnocephalus platyurus with the LC50 values around 1 mg l(-1)."( In vitro biotransformation of amitriptyline and imipramine with rat hepatic S9 fraction: evaluation of the toxicity with Spirotox and Thamnotoxkit F Tests.
Nałecz-Jawecki, G, 2008
)
0.35
"125% applied daily via chambers covering wounds in a full-thickness pig excision model has no overt toxic effect on wound healing as measured by wound contraction and histological assessment."( Safety evaluation of topically applied amitriptyline in porcine full-thickness wounds.
Bleiziffer, O; Eriksson, E; Gerner, P; Kudsi, Y; Pomahac, B; Velander, P; Zuhaili, B,
)
0.13
" There is also continuing controversy regarding the relative efficacy and adverse effects of right unilateral and bilateral ECT."( Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects.
Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009
)
0.35
"To test the hypotheses that, compared with placebo, concomitant treatment with nortriptline or venlafaxine during the ECT course enhances short-term efficacy without a meaningful effect on adverse effects and reduces the rate of post-ECT relapse, and to test the hypotheses that high-dose, right-sided, unilateral ECT is equivalent in efficacy to moderate-dosage bilateral ECT and retains advantages with respect to cognitive adverse effects."( Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects.
Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009
)
0.35
"Scores on the Hamilton Rating Scale for Depression, remission rate following completion of ECT, and selective measures of cognitive adverse effects."( Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects.
Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009
)
0.35
"Treatment with nortriptyline enhanced the efficacy and reduced the cognitive adverse effects of ECT relative to placebo."( Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects.
Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009
)
0.71
"The efficacy of ECT is substantially increased by the addition of an antidepressant medication, but such medications may differ in whether they reduce or increase cognitive adverse effects."( Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects.
Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009
)
0.35
"The limited use of nortriptyline for smoking cessation is likely due to concerns about its serious adverse effects."( Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis.
Chaiyakunapruk, N; Dhippayom, T; Jongchansittho, T, 2011
)
1.1
" Other adverse events significantly associated with nortriptyline were anticholinergic-related effects including drowsiness, dizziness, gastrointestinal disturbance and dysgeusia."( Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis.
Chaiyakunapruk, N; Dhippayom, T; Jongchansittho, T, 2011
)
1.02
"Current evidence suggests that nortriptyline, at doses between 75 and 100 mg, is not significantly associated with serious adverse events when administered in patients without underlying cardiovascular disease."( Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis.
Chaiyakunapruk, N; Dhippayom, T; Jongchansittho, T, 2011
)
1.06
"P450 genotype did not predict total side effect burden (nortriptyline: n = 251, p = 0."( Exploring the role of drug-metabolising enzymes in antidepressant side effects.
Aitchison, KJ; Craig, IW; Dernovšek, MZ; Dobson, RJ; Farmer, AE; Hauser, J; Henigsberg, N; Hodgson, K; Maier, W; McGuffin, P; Mors, O; Placentino, A; Rietschel, M; Souery, D; Tansey, KE; Uher, R, 2015
)
0.66
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Findings from in vitro aggregation and kinetics assays support the view that NOR inhibits aggregation of α-syn by directly binding to the soluble, monomeric form, and by enhancing reconfiguration of the monomer, inhibits formation of toxic conformations of the protein."( Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.
Collier, TJ; de Oliveira, P; Dettmer, U; Feany, MB; Grammatopoulous, T; Havas, D; Hutter-Paier, B; Jock, K; Justman, C; Lansbury, P; Lapidus, L; Liu, F; Paumier, KL; Prokesch, M; Rochet, JC; Sortwell, CE; Srivastava, KR; Stirtz, GL, 2017
)
1.9
" Seven patients withdrew due to mild adverse events (nortriptyline 1 and placebo 6)."( Efficacy and safety of nortriptyline in functional dyspepsia in Asians: A randomized double-blind placebo-controlled trial.
Kaosombatwattana, U; Leelakusolvong, S; Limsrivilai, J; Maneerattanaporn, M; Pongprasobchai, S; Tanwandee, T, 2018
)
1.04
"The cognitive adverse effects (AEs) of electroconvulsive therapy (ECT) limit the wider use of the treatment."( Reconsideration of the Benefits of Pharmacological Interventions for the Attenuation of the Cognitive Adverse Effects of Electroconvulsive Therapy.
Andrade, C, 2022
)
0.72
" For safety data, adverse events including tongue bitter taste or numbness were found in VC group to be greater than in nortriptyline group (61."( Efficacy and Safety of Vernonia cinerea for Smoking Cessation: An Open-Label Randomized Controlled Trial.
Budkaew, J; Chumworathayi, B; Sorncha, N; Tuenthosarn, K, 2023
)
1.12

Pharmacokinetics

The pharmacokinetic interaction between nortriptyline and terbinafine is probably due to inhibition of CYP2D6 of the nortripyline metabolism by terbinefine.

ExcerptReferenceRelevance
"A series of studies on the pharmacokinetic and pharmacodynamic properties of some tricyclic antidepressants is reviewed."( Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects.
Asberg, M, 1976
)
0.26
" The mean elimination half-life was 36."( Contribution to the pharmacokinetics of amitriptyline.
Ardekani, AB; Biggs, JT; Rosen, SH; Ziegler, VE, 1978
)
0.26
" 4 Compared with diazepam the tested drug has a longer plasma apparent half-life and a lower relative clearance."( Pharmacokinetics of N-demethyldiazepam in patients suffering from insomnia and treated with nortriptyline.
Alberti, GG; De Maio, D; Franciosi, P; Gomeni, R; Scieghi, G; Tognoni, G, 1975
)
0.47
"The compartmental model analysis by use of simultaneous curve fitting was carried out to ascertain the pharmacokinetic relationship between amitriptyline (AMT) and nortriptyline (NRT) in the serum and brain after acute or chronic oral administration of AMT."( Pharmacokinetic analysis of amitriptyline and its demethylated metabolite in serum and brain of rats after acute and chronic oral administration of amitriptyline.
Fukuchi, H; Kimura, M; Kimura, Y; Kitaura, T; Miyake, K, 1992
)
0.48
"A retrospective chart review was conducted on depressed inpatients to determine the economic impact of prospective pharmacokinetic dosing vs."( Cost-benefit analysis of prospective pharmacokinetic dosing of nortriptyline in depressed inpatients.
Browne, JL; Perry, PJ; Rickert, ED; Simmons, SA,
)
0.37
" The absence of correlation between clinical improvement and pharmacokinetic parameters is discussed for its possible significance."( Amitriptyline pharmacokinetics and clinical response: I. Free and total plasma amitriptyline and nortriptyline.
Baumann, P; Jonzier-Perey, M; Koeb, L; Lê, PK; Schöpf, J; Tinguely, D, 1986
)
0.49
"This is the final report of a study of single dose pharmacokinetic parameters of nortriptyline in children and adolescents 5 to 16 years old (N = 64)."( Child and adolescent nortriptyline single dose pharmacokinetic parameters: final report.
Carr, LG; Cooper, TB; Geller, B; Schluchter, MD; Warham, JE, 1987
)
0.82
" Coupled with its low affinity for muscarinic receptors, these kinetic and pharmacodynamic features of E-10-OH-NT call for further phase I studies."( Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects.
Bertilsson, L; Nordin, C; Otani, K; Resul, B; Scheinin, M; Siwers, B; Sjöqvist, F, 1986
)
0.53
" Methodological issues could account for some of the discrepancies in mean values of the pharmacokinetic parameters of amitriptyline."( Discrepancies between pharmacokinetic studies of amitriptyline.
Blaschke, TF; Dick, P; Hollister, L; Schulz, P,
)
0.13
"Eleven healthy volunteers were examined in a pharmacokinetic study."( Single oral dose pharmacokinetics of amitriptylinoxide and amitriptyline in humans.
Johannes, KJ; Jungkunz, G; Kuss, HJ, 1985
)
0.27
" Pharmacokinetic data on benzodiazepines thus in particular are important for design of dose, dose intervals and prediction (warning) about possible accumulation after repeated doses."( The contribution of pharmacokinetics to the best use of benzodiazepines and antidepressants.
Gram, LF, 1982
)
0.26
"The pharmacokinetic parameters of nortriptyline in the pediatric age group following oral administration of a single dose of 25 or 50 mg were investigated from nortriptyline plasma level assays at 12, 18, 24, 36, and 48 hours postdose."( Nortriptyline pharmacokinetic parameters in depressed children and adolescents: preliminary data.
Abel, AS; Anker, JA; Chestnut, E; Cooper, TB; Geller, B, 1984
)
1.99
" Evaluation of free, instead of total levels did not help to clarify the relationship between clinical and pharmacokinetic variables."( Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels.
Breyer-Pfaff, U; Brinkschulte, M; Gaertner, HJ; Kreuter, F; Scharek, G; Wiatr, R, 1982
)
0.48
" Subsequent plasma nortriptyline concentrations were used to calculate the half-life and clearance of the drug."( Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers.
Braithwaite, R; Crome, P; Dawling, S,
)
0.73
" 2 The median nortriptyline half-life was 25."( The pharmacokinetics of nortriptyline in patients with chronic renal failure.
Braithwaite, R; Dawlilng, S; Lynn, K; Rosser, R, 1981
)
0.93
"A combined pharmacodynamic and pharmacokinetic approach was made to study the pharmacodynamic half-life (Pd1/2) of amitriptyline (AT)."( Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life.
Ghose, K, 1980
)
0.26
" The mean plasma half-life and AUC of amitriptyline oxide and its metabolites were significantly higher in patients than in healthy adults."( [Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure].
Degen, J; Fischer, W; Höxter, G; Pintar, P; Seiberling, M; Steinhauer, HB; Wölke, E, 1993
)
0.29
" Pharmacodynamic analyses showed that patients with moderate to severe anticholinergic side effects [CSE(+)] had significantly higher NT levels than those with mild or no symptoms [CSE(-)]."( Clinical relevance of serum nortriptyline and 10-hydroxy-nortriptyline measurements in the depressed elderly: a multicenter pharmacokinetic and pharmacodynamic study.
Ahmed, SK; Amin, M; Holm, P; Katona, C; Kin, NM; Klitgaard, N; Kragh-Sorensen, P; Nair, NP; Schwariz, G; Stage, K, 1996
)
0.59
"Case report of a pharmacokinetic interaction between diltiazem and nortriptyline."( Pharmacokinetic interaction between diltiazem and nortriptyline.
Hoppel, CL; Krähenbühl, S; Smith-Gamble, V, 1996
)
0.78
" Calculation of nortriptyline clearances and half-life by formulae used routinely in therapeutic drug monitoring."( Pharmacokinetic interaction between diltiazem and nortriptyline.
Hoppel, CL; Krähenbühl, S; Smith-Gamble, V, 1996
)
0.89
"There is a significant pharmacokinetic interaction between diltiazem and nortriptyline, which is probably due to a reduction in the first pass clearance of nortriptyline, leading to an increase in its bioavailability."( Pharmacokinetic interaction between diltiazem and nortriptyline.
Hoppel, CL; Krähenbühl, S; Smith-Gamble, V, 1996
)
0.78
"Subjects who were homozygous for CYP2D6*10 had significantly higher total areas under the plasma concentration-time curve (AUC), lower apparent oral clearances, and longer mean plasma half-life of nortriptyline than subjects in the CYP2D6*1/*1 and the heterozygous groups."( Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.
Bertilsson, L; Dahl, ML; Dalén, P; Sjöqvist, F; Tybring, G; Yue, QY; Zhong, ZH, 1998
)
0.81
"Sampling times for Bayesian estimation of the pharmacokinetic parameters of an antidepressant drug, nortriptyline, during its therapeutic drug monitoring were optimized."( Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring.
Mentré, F; Merlé, Y, 1999
)
0.74
"The relative contribution of cytochrome P450 3A (CYP3A) to the oral clearance of amitriptyline in humans has been assessed using a combination of in vitro approaches together with a clinical pharmacokinetic interaction study using the CYP3A-selective inhibitor ketoconazole."( Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies.
Corbett, KE; Ehrenberg, BL; Graf, JA; Greenblatt, DJ; Harmatz, JS; Mertzanis, P; Rodriguez, MC; Schmider, J; Shader, RI; Venkatakrishnan, K; von Moltke, LL, 2001
)
0.31
" At the end of each study week, the steady-state pharmacokinetic parameters of nortriptyline or paroxetine were determined within the dose interval."( Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Andersson, K; Bertilsson, L; Härtter, S; Laine, K; Svensson, JO; Tybring, G; Widén, J, 2001
)
0.75
"The pharmacokinetic interaction between nortriptyline and terbinafine is probably due to inhibition of CYP2D6 of the nortriptyline metabolism by terbinafine."( Pharmacokinetic interaction between nortriptyline and terbinafine.
Kempen, RW; Van Den Heuvel, HA; Van Der Kuy, PH; Vanmolkot, LM, 2002
)
0.86
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" This method was successfully applied to the pharmacokinetic study in rats after intravenous injection of amitriptyline hydrochloride."( Validated LC-MS (ESI) assay for the simultaneous determination of amitriptyline and its metabolite nortriptyline in rat plasma: application to a pharmacokinetic comparison.
Li, HD; Liu, YW; Shen, Y; Xu, P; Zhu, RH, 2010
)
0.58
" The developed assay was applied to a pharmacokinetic study in humans."( Development and validation of a highly sensitive LC-MS/MS method for simultaneous quantitation of nortriptyline and 10-hydroxynortriptyline in human plasma: application to a human pharmacokinetic study.
Bharathi, DV; Hotha, KK; Jagadeesh, B; Kumar, KK; Mullangi, R; Rao, DV; Ravindranath, LK; Reddy, YR; Veera, KN, 2010
)
0.58
" Therefore to study this we have applied the population based pharmacokinetic simulator Simcyp."( Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator.
Jensen, KG; Jornil, J; Larsen, F; Linnet, K, 2011
)
0.66
" Therefore, it was decided to study a potential pharmacokinetic interaction between the nonnucleoside reverse transcriptase inhibitor nevirapine (NVP) and the tricyclic antidepressant nortriptyline (NT)."( Pharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptyline.
Gandía, P; Melis, V; Peris, JE; Usach, I, 2014
)
0.85
" Non-compartmental pharmacokinetic analyses were performed."( Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs.
KuKanich, B; Norkus, C; Rankin, D, 2015
)
0.64
" Noncompartmental pharmacokinetic analyses were performed."( Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs.
KuKanich, B; Norkus, C; Rankin, D, 2015
)
0.64
" The gene variations of CYP2C19 and CYP2D6 did not change the pharmacodynamic effect."( A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans.
Choi, HY; Choi, SE; Hwang, IY; Kim, JM; Kim, YR; Lee, JG; Lee, JH; Lim, HS; Na, HS; Oh, WY; Park, S; Park, ZW; Ryu, S, 2017
)
0.46
" To that end, we developed a mechanistic physiologically based pharmacokinetic model of the heart."( Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification.
Mendyk, A; Polak, S; Tylutki, Z, 2018
)
0.48
" NVP was administered orally to male and female rats and sex differences in plasma levels and pharmacokinetic parameters were analysed."( Sex-dependent metabolism of nevirapine in rats: impact on plasma levels, pharmacokinetics and interaction with nortriptyline.
Compañ, P; Peris, JE; Usach, I, 2018
)
0.69
" Serial blood draws for pharmacokinetic analysis were made after a single oral 25-mg dose of amitriptyline was administered."( Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.
Bae, KS; Choi, HY; Choi, SE; Kim, KS; Koh, A; Lim, HS; Pak, KC; Ryu, S, 2019
)
0.71
" Similar trends of fluoxetine and amitriptyline pharmacokinetic parameters were revealed in volunteers and animals."( Experimental and Clinical Pharmacokinetics of Fluoxetine and Amitriptyline: Comparative Analysis and Possible Methods of Extrapolation.
Gneushev, ET; Kondratenko, SN; Kukes, VG; Savelyeva, MI; Shikh, EV, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
"The drug-drug interactions with fluoxetine, a pure serotonergic reuptake blocker with a unique profile of side effects, have not been studied adequately."( Drug-drug interactions of fluoxetine with tricyclics.
von Ammon Cavanaugh, S, 1990
)
0.28
"Nortriptyline combined with transdermal nicotine resulted in an increased cessation rate with little effect on withdrawal symptoms."( A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation.
Fryer, GE; Kick, S; Miyoshi, T; Prochazka, AV; Steinbrunn, C, 2004
)
2.08
" In conclusion, both Risp and OH-Risp interact with P-gp in vitro, and P-gp has a profound effect on Risp and OH-Risp distribution over the BBB, as is evident from the knock-out mice experiments."( P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments.
Ejsing, TB; Linnet, K; Pedersen, AD, 2005
)
0.33

Bioavailability

The first-pass equation based on the dose, hepatic blood flow, and total area under the plasma level-time curve after oral administration was used retrospectively to predict the bioavailability of nortriptyline. There was no consistent effect on the metabolism of dicumarol following treatment with amitriptylines.

ExcerptReferenceRelevance
" There was no consistent effect on the metabolism of dicumarol following treatment with amitriptyline or nortriptyline although the bioavailability of dicumarol appeared to be increased."( Effects of tricyclic antidepressants on drug metabolism.
Birkett, DJ; Graham, GG; Pond, SM; Wade, DN, 1975
)
0.47
" This proves that the difference in bioavailability between the two routes of administration was due to first pass metabolism."( First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma.
Alván, G; Borga, O; Lind, M; Palmér, L; Siwers, B, 1977
)
0.55
"The first-pass equation based on the dose, hepatic blood flow, and total area under the plasma level-time curve after oral administration was used retrospectively to predict the bioavailability of nortriptyline after oral administration of 1 mg/kg-single oral doses to monozygotic and dizygotic twin pairs."( Comparison of observed and predicted bioavailability of nortriptyline in humans following oral administration.
Gibaldi, M, 1975
)
0.69
" It was assumed that pretreatment with cimetidine, because of its inhibition of metabolic pathways of both demethylation and hydroxylation as well as its ability to reduce hepatic extraction of these drugs, would increase bioavailability and decrease clearance of both drugs."( Cimetidine interaction with imipramine and nortriptyline.
Henauer, SA; Hollister, LE, 1984
)
0.53
" The metabolic acidosis associated with the seizures may have caused hypotension by direct cardiotoxicity, an increase in bioavailability of tricyclic antidepressant because of changes in protein binding, an alteration of the effects of tricyclic antidepressant on cardiac membrane sodium channels, or a combination of these mechanisms."( Recurrent hypotension immediately after seizures in nortriptyline overdose.
Bell, A; Gaynor, B; Lipper, B, 1994
)
0.54
"The average plasma concentration of nortriptyline at steady state (Css) divided by the amount of nortriptyline administered per time rose significantly in a patient with concomitant administration of diltiazem, suggesting increased bioavailability and/or decreased clearance of nortriptyline."( Pharmacokinetic interaction between diltiazem and nortriptyline.
Hoppel, CL; Krähenbühl, S; Smith-Gamble, V, 1996
)
0.82
" After an acute intraperitoneal (IP) administration of amitriptyline (AMI) to male Sprague-Dawley rats we found that: (i) its absorption rate is rapid; (ii) its elimination half-life is much shorter than in humans; and (iii) its levels largely exceeded those of its metabolites."( Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after one and six half-life repeated administrations to rats.
Besson, A; Coudore, F; Eschalier, A; Fialip, J; Lavarenne, J, 1996
)
0.29
" Food intake did not consistently or significantly influence the bioavailability of either AMI or NT, nor the demethylation of AMI, nor the hydroxylation or the primary or secondary conjugation of NT."( Food intake and the presystemic metabolism of single doses of amitriptyline and nortriptyline.
Lidén, A; Liedholm, H, 1998
)
0.53
" The relative bioavailability with respect to a reference preparation for AUC related to amitriptyline (CAS 50-48-6) was 99."( [The bioequivalence of a new amitriptyline tablet formulation in comparison with a reference preparation].
Buchberger, D; Dilger, C; Läuter, J; Metzner, JE; Schmidt, U, 1998
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Assuming 100% absorption, the model allows systemic clearance and bioavailability to be estimated."( Quantitative pharmacogenetics of nortriptyline: a novel approach.
Al-Shurbaji, A; Alván, G; Dahl, ML; Kvist, EE; Nordin, C; Ståhle, L, 2001
)
0.59
" It constitutes an important part of the blood-brain barrier and actively exports a number of molecules across the blood-brain barrier back into the vascular space, subsequently reducing central nervous system (CNS) bioavailability of these substances."( P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline.
Grauer, MT; Uhr, M, 2004
)
0.32
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Bioavailability of oral amitriptyline was 6%."( Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs.
KuKanich, B; Norkus, C; Rankin, D, 2015
)
0.64
" The relative bioavailability of amitriptyline in fasted dogs compared to fed dogs was 69-91% (n = 3)."( Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs.
KuKanich, B; Norkus, C; Rankin, D, 2015
)
0.64
" The bioavailability parameters of the test drugs in dogs and volunteers did not differ."( Experimental and Clinical Pharmacokinetics of Fluoxetine and Amitriptyline: Comparative Analysis and Possible Methods of Extrapolation.
Gneushev, ET; Kondratenko, SN; Kukes, VG; Savelyeva, MI; Shikh, EV, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

We tested nine symptom dimensions derived from a previously published factor analysis of depression rating scales as predictors of outcome. 811 adults with moderate to severe depression treated with flexibly dosed escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP)

ExcerptRelevanceReference
" In determination of the optimal individual dosage must continue to be an empirical process based on clinical observations and experience."( [Correlation between plasma concentration and clinical effect of neuroleptics and antidepressants].
Modestin, J; Petrin, A, 1976
)
0.26
" No alteration of plasma half-life of warfarin, phenytoin, or tolbutamide was observed following dosage with the tricyclic antidepressants used."( Effects of tricyclic antidepressants on drug metabolism.
Birkett, DJ; Graham, GG; Pond, SM; Wade, DN, 1975
)
0.25
" In an ordinary psychiatric department, 34 patients had their NT level checked the second week of treatment and their dosage subsequently adjusted, if it was outside the recommended therapeutic plasma range (50--150 ng/ml)."( The practical significance of nortriptyline plasma control. A prospective evaluation under routine conditions in endogenous depression.
Hvidberg, EF; Kragh-Sørensen, P; Larsen, NE; Sørensen, B, 1978
)
0.55
" Important factors which influence this situation are the diagnostic criteria used to select patients for drug treatment, the dosage prescribed and individual compliance."( The role of plasma level monitoring of tricyclic antidepressant drugs as an aid to treatment.
Braithwaite, R, 1979
)
0.26
" The results of the investigation were: (1) long-term treatment with nortriptyline is followed by hyposecretion or xerostomia, (2) the reduction of the secretion is reversible, (3) re-establishment of treatment with dosage leading to the same serum level of nortriptyline is immediately followed by a drop in saliva secretion, and (4) the changes in salivary secretion are useful as an indicator of side effects."( Saliva secretion following long-term antidepressant treatment with nortriptyline controlled by plasma levels.
Bertram, U; Kragh-Sørensen, P; Larsen, NE; Rafaelsen, OJ, 1979
)
0.73
" The test is useful for dosage adjustment to maximise antidepressant action and minimise toxicity."( Dosage adjustment from simple nortriptyline spot level predictor tests in depressed patients.
Braithwaite, RA; Dawling, S; McAuley, R; Montgomery, DB; Montgomery, SA,
)
0.42
" Drugs were administered according to a flexible dosage varying from 50 mg to 125 mg/day, subdivided in 2-3 doses."( [Controlled clinical trial of nomifensine in treatment of depression (author's transl)].
Ardito, P; Ferrara, M; Zaccara, G,
)
0.13
" Plasma level determinations can never replace sound clinical judgment and dosage adjustment for individual patients."( The role of plasma concentrations in the use of tricyclic antidepressant drugs.
Levine, RR, 1979
)
0.26
" Ten of them received amitriptyline in a daily dosage of 20-75 mg for 53 weeks (average); in 2, electrocardiographic side effects developed, viz, inversion of the T waves or evidence of acute coronary insufficiency."( Cardiovascular side effects of long-term therapy with tricyclic antidepressants in the aged.
Oei, LS; Rodstein, M, 1979
)
0.26
"The authors describe a technique that enables a physician to determine individual patient dosage requirements for nortriptyline from a single 24-hour blood sample."( Prediction of individual dosage of nortriptyline.
Cooper, TB; Simpson, GM, 1978
)
0.75
" This fraction is higher than that reported previously when intravenous nortriptyline was used as the reference dosage form."( First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma.
Alván, G; Borga, O; Lind, M; Palmér, L; Siwers, B, 1977
)
0.78
"Steady-state nortriptyline plasma levels were determined in eight patients at 9 AM, 12 PM, 3 PM, and 6 PM during treatment with nortriptyline hydrochloride administered as a single daily bedtime (hs) dose at 10 PM and repeated after changing the dosage schedule to three times a day (tid) with divided doses at 10 AM, 4 PM, and 10 PM."( Sampling time, dosage schedule, and nortriptyline plasma levels.
Biggs, JT; Knesevich, JW; Wylie, LT; Ziegler, VE, 1977
)
0.9
"Fifteen depressed patients were treated with amitriptyline in a dosage ranging from 75 mg to 200 mg/day for a minimum of three weeks, two of which were at a fixed dosage."( Electrocardiographic findings in patients undergoing amitriptyline treatment.
Biggs, JT; Ziegler, VE, 1977
)
0.26
" The amounts of drug material in suckling neonates from nursing rabbits dosed repeatedly with the two drugs were also measured."( Studies of excretion in rabbit milk after administration of carbon-14 labelled amitriptyline and nortriptyline.
Aaes-Jorgensen, T; Jorgensen, A, 1977
)
0.47
" After clinical diagnoses were determined, patients entered a double-blind protocol (amitriptyline or placebo) and their clinical status was determined with the Hamilton Depression Rating Scale by raters blind to the drug type, its dosage and plasma levels."( Amitriptyline plasma levels and clinical response in primary depression.
Coble, P; Grau, T; Hanin, I; Kupfer, DJ; Spiker, DG, 1977
)
0.26
" Dosage was 1-3 mg daily."( Effect of flupenthixol on depression with special reference to combination use with tricyclic antidepressants. An uncontrolled pilot study with 45 patients.
Baba, O; Fujiwara, J; Hanaoka, M; Ishino, H; Sasaki, K, 1976
)
0.26
"The extent of first-pass metabolism of nortriptyline, calculated by comparing the areas under the plasma concentration-time curves following intravenous and oral dosing in six individuals, varied from 41 to 54%."( Comparison of observed and predicted first-pass metabolism of nortriptyline in humans.
Niazi, S, 1976
)
0.77
" Studies on the variation in steady-state plasma levels are described on a fixed oral dosage of nortriptyline."( The measurement of plasma levels of tricyclic antidepressant drugs.
Burrows, GD; Coghlan, JP; Davies, B; Maguire, K; Scoggins, BA, 1976
)
0.47
" Dose-response graphs for the tyramine pressor effect were shifted to the right during the antidepressant treatment, indicating a blockade of the membrane pump in peripheral sympathetic terminals."( Effect of tricyclic antidepressants and alcohol in psychomotor skills related to driving.
Elonen, E; Linnoila, M; Mäki, M; Mattila, MJ; Seppälä, T, 1975
)
0.25
" This variation was not significantly affected by the dosage schedule, the time of sampling after an oral dose, or the storage of the plasma samples."( Rapid radioisotopic procedure for determination of nortriptyline in plasma.
Burrows, GD; Coghlan, JP; Maguire, KP; Scoggins, BA, 1976
)
0.51
" The presence of PG generally enhanced the absorption of each drug, and the degree of enhancement appeared to be related to the percentage of PG in the dosing solution."( Propylene glycol as a vehicle for percutaneous absorption of therapeutic agents.
Bailey, DN,
)
0.13
" The research strategy, in accordance with a dose-response paradigm, was to determine which of the early changes in emotion and behaviour found in treatment responders were systematically associated with plasma concentrations of amitriptyline or its major metabolite."( Identifying the specific clinical actions of amitriptyline: interrelationships of behaviour, affect and plasma levels in depression.
Bowden, CL; Casper, RC; Frazer, A; Katz, MM; Kocsis, J; Koslow, SH; Maas, JW; Secunda, S, 1991
)
0.28
" Using the weight-adjusted dosage schedule, 18 of the 21 patients attained plasma concentrations of nortriptyline within the presumed therapeutic range; however, no clear relationship could be established between plasma concentrations and clinical response."( Simulated home treatment of depression with nortriptyline.
Hollister, L; Peabody, C; Van Norman, J; Warner, D, 1991
)
0.76
" Imipramine and nortriptyline also caused a rightward shift in the dose-response curve of histamine-induced cAMP generation."( Tricyclic antidepressants and acid secretory response of rabbit gastric cells.
Batzri, S, 1985
)
0.62
" S1 served as a control and at S2-4 oxotremorine dose-response curves were taken expressing the dose-related inhibition of the evoked release of [3H]norepinephrine as percentage of the control."( Antagonism by tricyclic antidepressants of the muscarinic receptors located on the adrenergic nerve endings in rabbit heart atrium.
Perel, JM; Somogyi, GT, 1989
)
0.28
"The linearity of the (AMT) kinetics of amitriptyline has been tested in 135 depressed dosed twice daily by measuring plasma."( Amitriptyline: linear or nonlinear kinetics in every day practice?
Allers, G; Bertschy, G; Vandel, B; Vandel, S; Volmat, R, 1989
)
0.28
"The postulated therapeutic activity of nortriptyline metabolites has prompted investigation of dosage adjustments based on plasma levels of nortriptyline (NT) and its metabolites."( Relationships among nortriptyline, 10-OH(E)nortriptyline, and 10-OH(Z)nortriptyline steady-state plasma levels and nortriptyline dosage.
Hurst, HE; Jones, DR; Lukey, BJ; Wright, JH, 1989
)
0.87
" In a sulpiride-treated patient, the dosage was reduced in four steps over a nine-week period and a curvilinear relationship was demonstrated between central D2-dopamine receptor occupancy and serum drug concentrations."( Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.
Farde, L; Halldin, C; Sedvall, G; Wiesel, FA, 1988
)
0.27
"A retrospective chart review was conducted on depressed inpatients to determine the economic impact of prospective pharmacokinetic dosing vs."( Cost-benefit analysis of prospective pharmacokinetic dosing of nortriptyline in depressed inpatients.
Browne, JL; Perry, PJ; Rickert, ED; Simmons, SA,
)
0.37
"The incidence of potentially toxic serum levels (greater than or equal to 400 ng/ml) was analyzed in a group of 196 monitored patients on a standard dosage regimen (75-225 mg/day) of several antidepressants: imipramine, amitriptyline, nortriptyline, maprotiline and clomipramine."( High levels of tricyclic antidepressants in conventional therapy: determinant factors.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Gutierrez, JR; Tamayo, M, 1988
)
0.46
" In addition, after 6 weeks of dosing patients estimated their percentage of pain in comparison with baseline."( Analgesic and antidepressive effects of low-dose amitriptyline in relation to its metabolism in patients with chronic pain.
de Wolff, FA; Edelbroek, PM; Linssen, AC; Rooymans, HG; Zitman, FG, 1986
)
0.27
" Severe toxicity usually occurs at supratherapeutic plasma levels and might be prevented by tailoring the dosage according to the individual's drug hydroxylating capacity."( Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation.
Bertilsson, L; Sjöqvist, F, 1986
)
0.27
" A nomogram was made from the regression equations to predict the dosage required to achieve a steady state concentration within a 50 to 150 ng/ml range."( Prediction of individual dosage of nortriptyline in depressed elderly outpatients.
Cooper, TB; Schneider, LS; Sloane, RB; Staples, FR, 1987
)
0.55
" A twice a day dosage regimen is recommended for the entire 5- to 16-year-old group based on their range of half-lives."( Child and adolescent nortriptyline single dose pharmacokinetic parameters: final report.
Carr, LG; Cooper, TB; Geller, B; Schluchter, MD; Warham, JE, 1987
)
0.59
" These preliminary data suggest that smokers ideally should be dosed at the lower end of the nortriptyline therapeutic range, whereas nonsmokers should be dosed at the upper end to maximize the antidepressant effect and minimize adverse effects."( Effects of smoking on nortriptyline plasma concentrations in depressed patients.
Alexander, B; Browne, JL; Perry, PJ; Prince, RA; Tsuang, MT, 1986
)
0.81
" The clinical uses of TCA plasma level-response studies are discussed in relationship to rational dosage adjustment to increase response rates and avoid iatrogenic toxicity."( Nortriptyline pharmacokinetics and plasma levels: implications for clinical practice.
Biggs, JT; Preskorn, SH; Rubin, EH, 1985
)
1.71
" Concurrently the effect of nortriptyline low dosage therapy was studied in 21 women suffering from motor or sensory urgency and urge incontinence."( Selective effect of nortriptyline on smooth muscle as an anticholinergic drug: a pharmacological and clinical study.
Cohen, S; Katz, A; Nissenkorn, I; Rubinstein, R, 1986
)
0.89
" The large individual variation in the pharmacokinetics of the tricyclic antidepressants makes prediction of plasma level from dosage in a given individual virtually impossible without knowledge of rate of elimination and apparent volume of distribution."( Relationship between plasma level and therapeutic effect of nortriptyline.
Asberg, M; Crönholm, B; Sjöqvist, F; Tuck, D, 1971
)
0.49
" Increasing doses of nortriptyline produced a parallel shift of the hypothermic log dose-response curve for intraventricular injections of noradnamine to the right."( The interactions of noradnamine and imipramine-like antidepressant drugs.
Cowell, P, 1969
)
0.57
" The ED50s of the effective neuroleptics for this inhibition were similar to those reported for antagonism of amphetamine-induced stereotypic behavior in the rat and the slopes of the dose-response curves were parallel indicating a common site and mechanism of action, presumably blockade of postsynaptic dopaminergic receptors."( Effect of neuroleptics and tricyclic antidepressants upon d-amphetamine discrimination.
Schechter, MD, 1980
)
0.26
" Severe toxicity usually occurs at supratherapeutic plasma levels and might be prevented by tailoring the dosage according to the individual's drug hydroxylating capacity."( Clinical pharmacology of antidepressant drugs: pharmacogenetics.
Bertilsson, L; Sjöqvist, F, 1984
)
0.27
" Plasma level determinations after 2 and 6 weeks of treatment revealed that moderately significant correlations existed between AT plasma levels and clinical improvement, dosage intake, age, weight, sex, and coffee intake."( Tricyclic plasma levels in depressed outpatients treated with amitriptyline.
Case, G; Hucker, H; Rickels, K; Weise, C, 1983
)
0.27
"It is important to understand both the kinetic and the dynamic implications of dosing TCAs and BZs in the elderly, for whom these drugs are frequently prescribed."( Implications of dosing tricyclic antidepressants and benzodiazepines in geriatrics.
Cutler, NR; Narang, PK, 1984
)
0.27
"Twenty-one depressed patients participated in a study that assessed the predictability of amitriptyline (AT) dosage based on plasma drug concentrations after a single dose."( Single-dose single-point method in amitriptyline therapy.
Khazanie, PG; Madakasira, S; Sato, TL, 1984
)
0.27
" When DMI dosage was raised after an initial steady state had been reached, the rise in plasma DMI level was proportionately greater than the increase in dosage, suggesting saturation of DMI elimination pathways."( The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma.
Cooke, RG; Persad, E; Reed, KL; Stancer, HC; Warsh, JJ, 1984
)
0.27
"7 hours) than some adult groups and twice a day dosage would, therefore, be more appropriate for many children."( Nortriptyline pharmacokinetic parameters in depressed children and adolescents: preliminary data.
Abel, AS; Anker, JA; Chestnut, E; Cooper, TB; Geller, B, 1984
)
1.71
"This study compared two prospective pharmacokinetic dosing methods to predict steady-state concentrations of nortriptyline."( Two prospective dosing methods for nortriptyline.
Alexander, B; Browne, JL; Dunner, FJ; Perry, PJ; Sherman, AD; Tsuang, MT,
)
0.62
" The concentration of amitriptyline plus nortriptyline in a blood sample taken 24 hours later was used to predict by means of a nomogram the amitriptyline dosage required for each patient."( Amitriptyline dosage prediction in elderly patients from plasma concentration at 24 hours after a single 100mg dose.
Dawling, S; Ford, S; Lewis, RR; Rangedara, DC,
)
0.4
" Dosage was adjusted based on plasma level with the aim of achieving a concentration of 60-180 ng/ml."( Amitriptyline and nortriptyline response profiles in unipolar depressed patients.
Bowden, CL; Lehmann, LS; Redmond, FC; Stanton, BC, 1982
)
0.6
" The results of the investigation were: (1) long-term treatment with nortriptyline is followed by hyposecretion or xerostomia, (2) the reduction of the secretion is reversible, (3) re-establishment of treatment with dosage leading to the same serum level of nortriptyline is immediately followed by a drop in saliva secretion, and (4) the changes in salivary secretion are useful as an indicator of side effects."( Saliva secretion following long-term antidepressant treatment with nortriptyline controlled by plasma levels.
Bertram, U; Kragh-Sørensen, P; Larsen, NE; Rafaelsen, OJ, 1981
)
0.73
" Compared to the recommended therapeutic ranges, wild inter-individual differences were observed in plasma drug concentration, even when corrections for dosage were made."( Monitoring of tricyclic antidepressant therapy.
Dawling, S, 1982
)
0.26
"The "single-point, single-dose" method for predicting individual maintenance dosage is examined."( Further considerations of the "single-point single-dose" method to estimate individual maintenance dosage requirements.
Rowland, M; Unadkat, JD, 1982
)
0.26
" These dosage regimes provided a mean observed steady-state nortriptyline concentration of 104 micrograms."( Nortriptyline therapy in elderly patients: dosage prediction from plasma concentration at 24 hours after a single 50 mg dose.
Crome, P; Dawling, S; Heyer, EJ; Lewis, RR, 1981
)
1.95
" Out of regard for the administrative and psychological advantages of the once-a-day dosage this form should be preferred, not least in the out-patient treatment with nortriptyline of endogenous depression."( Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day.
Pedersen, JH; Sørensen, JL, 1980
)
0.68
"In 21 patients suffering from endogenous depression and given nortriptyline 150 mg/day for 4 weeks in a once-a-day dosage an electrocardiographic study was made with ECG recordings at different times during the treatment."( ECG changes during treatment with nortriptyline in a once-a-day dosage.
Nielsen, JL, 1980
)
0.78
" Mean steady state plasma concentrations during the two dosage regimens were similar."( Plasma concentrations of amitriptyline during single nightly and thrice daily administration. Cross-over study.
Ascalone, V; Cisternino, M; De Maio, D; Drago, F; Nielsen, P, 1980
)
0.26
" From such kowledge it should be possible to individualize drug dosage regimes so as to maximize antidepressant action, while at the same time minimizing the risk of toxicity."( The prediction of tricyclic antidepressant plasma concentrations.
Braithwaite, RA; Dawling, S; McAuley, R; Montgomery, SA, 1980
)
0.26
" For depressive neurosis and involutional melancholia best therapeutic responses were yielded at a dosage of 50 mg, while in the treatment of manic-depressive illness, comparable results occurred at a 150 mg dosage."( Amitriptyline, nortriptyline plasma levels and clinical response in women with affective disorders.
Corona, GL; Cucchi, ML; Fenoglio, L; Frattini, P; Pinelli, P; Santagostino, G; Zerbi, F, 1980
)
0.61
"Amitriptyline and nortriptyline plasma levels were measured in depressed outpatients 24 hours after a single dose of amitriptyline and following chronic dosing to steady state."( Prediction of steady-state plasma levels of amitriptyline and nortriptyline from a single dose 24 hr. level in depressed patients.
Amsterdam, J; Brunswick, DJ; Mendels, J; Rothbart, M; Sandler, K; Schless, A, 1980
)
0.84
" It was necessary to adjust nortriptyline dosage in < 20% of patients to maintain serum levels within the postulated therapeutic window of 50-170 ng/ml."( Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo.
Amin, M; Holm, P; Katona, C; Klitgaard, N; Kragh-Sørensen, P; Kühn, H; Leek, CA; Nair, NP; Ng Ying Kin, NM; Stage, KB, 1995
)
0.93
"Nortriptyline hydrochloride prescribed by primary care physicians trained in clinical guidelines specifying dosage schedules, durations, and procedures resembling those recommended by the AHCPR (Agency for Health Care Policy and Research) Depression Guideline Panel."( Applicability of clinical pharmacotherapy guidelines for major depression in primary care settings.
Block, MR; Lave, J; Madonia, MJ; Rodriguez, E; Schulberg, HC; Scott, CP, 1995
)
1.73
" In many instances, a knowledge of the drug metabolism status of a patient can be helpful in the selection of a drug and its dosage regimen, and in the prediction of possible drug/drug interactions when two or more drugs have to be administered concomitantly."( Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.
Coutts, RT, 1994
)
0.29
"0 kg) were dosed on a daily basis with 20 mg/kg nortriptyline (NT) prior to feeding for a period of five days."( The use of bone marrow in the study of postmortem redistribution of nortriptyline.
Morris, EM; Wahba, WW; Winek, CL,
)
0.62
" Blood level:dose ratios and dose-response relationships for cyclosporine were virtually identical in all three groups before and during treatment."( Fluoxetine and cyclosporine in organ transplantation. Failure to detect significant drug interactions or adverse clinical events in depressed organ recipients.
Fairbanks, LA; Fawzy, FI; Skotzko, CE; Strouse, TB,
)
0.13
" The mean area under the curve for the sum of amitriptyline and nortriptyline concentrations was 42% higher with concomitant divalproex dosing than it was for dosing with amitriptyline alone."( Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics.
Awni, WM; Cavanaugh, J; Granneman, GR; Shi, H; Wong, SL, 1996
)
0.79
" In addition, drug interactions, nonlinear kinetics and dosing habits were studied with other techniques corroborating previous results and adding new information."( Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response.
Jerling, M,
)
0.13
" Genotyping of subjects with multiple copies of functional genes may be of great value for differentiating ultrarapid metabolizers from patients who do not comply with the prescription and for assuring adequate drug choice and dosage for these patients."( 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes.
Bernal Ruiz, ML; Bertilsson, L; Dahl, ML; Dalén, P; Nordin, J, 1998
)
0.62
"A sensitive spectrophotometric method for the determination of amitriptyline hydrochloride, nortriptyline hydrochloride and doxepin hydrochloride in pure and dosage forms, is described."( Spectrophotometric determination of some antidepressant drugs using 3-methylbenzothiazolin-2-one hydrazone.
Manju, B; Revanasiddappa, HD, 1999
)
0.52
" This group of children and adolescents tolerated robust dosing of NT well, with few clinical or cardiovascular adverse events."( A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder.
Biederman, J; Bostic, JQ; Millstein, R; Polisner, DA; Prince, JB; Spencer, TJ; Wilens, TE, 2000
)
0.62
"A spectrophotometric procedure is described for determination of nortriptyline hydrochloride in pure and dosage form as well as in the presence of its degradate."( Stability indicating method for determination of nortriptyline hydrochloride using 3-methyl-2-benzothiazolinone hydrazone (MBTH).
Abbas, SS; El Ragehy, NA; El-Khateeb, SZ, 2001
)
0.8
"Paroxetine, with a daily dosage from 20 to 40 mg, is an effective tool in normalizing the metabolic status of CYP2D6 ultrarapid metabolizers."( Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Andersson, K; Bertilsson, L; Härtter, S; Laine, K; Svensson, JO; Tybring, G; Widén, J, 2001
)
0.52
" Significant correlations were found between the numbers of alleles encoding decreased metabolism and nortriptyline plasma concentration, nortriptyline dose, and nortriptyline plasma concentration standardized for dose, indicating a gene dosage effect."( CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression.
Cheuk, W; Kirshner, MA; Mulsant, BH; Murphy, GM; Pascoe, N; Pollock, BG; Reynolds, CF, 2001
)
0.77
" Gene dose has a significant impact on drug pharmacokinetics and prior knowledge of it may aid in predicting plasma concentration of the drug and thus tailoring patient-specific dosage regimens."( Quantitative pharmacogenetics of nortriptyline: a novel approach.
Al-Shurbaji, A; Alván, G; Dahl, ML; Kvist, EE; Nordin, C; Ståhle, L, 2001
)
0.59
" Various dosage forms of nicotine replacement therapy increase smoking quit rates relative to placebo, but they generally do not result in 1-year quit rates of over 20%."( Effect of nonnicotine pharmacotherapy on smoking behavior.
Golding, M; Hatsukami, DK; Jamerson, BD; Kotlyar, M, 2001
)
0.31
" These include the currently available dosage forms of nicotine replacement therapy (gum, patch, nasal spray, and inhaler) and bupropion."( Managing nicotine addiction.
Hatsukami, DK; Kotlyar, M, 2002
)
0.31
"Patients with major depression (ICD 10: F31-F33) and a HAMD-21 total score of 15-41 received At on a dosage schedule chosen by the doctor for at least 4 wks."( Predictors of therapeutic effects in amitriptyline treatment--1. Plasma drug levels.
Franke, L; Müller-Oerlinghausen, B; Schewe, HJ; Uebelhack, R, 2003
)
0.32
" Mechanisms of desipramine toxicity and its dosage recommendations are discussed."( Excess fatality from desipramine and dosage recommendations.
Amitai, Y; Frischer, H, 2004
)
0.32
" Conventional dosage regimen led to toxic plasma concentration of NT and adverse effects such as dry mouth, constipation, and dizziness in this case with genotype CYP2D6*5/*10B."( A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.
Hong, KS; Ki, CS; Kim, JW; Lee, SY, 2004
)
0.55
" However, in the present case, the abnormal ECG findings occurred following a usual dosage of nortriptyline."( [A case of Brugada syndrome with convulsive seizure during antidepressant administration: relation of antidepressant agents and arrhythmia leading to sudden death].
Aihara, H; Aonuma, K; Asada, T; Endo, G; Hori, T; Tanimukai, S, 2006
)
0.55
" No difference was found in AT daily dosage between PMs (median 25 mg day(-1); range 5-80) and extensive metabolizers (EMs) (median 27."( The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.
Brosen, K; Halling, J; Weihe, P, 2008
)
0.58
"Two simple, sensitive and rapid extractive spectrophotometric methods have been developed for the assay of the antidepressant drug nortriptyline (NOR) hydrochloride in pure form and in different dosage forms."( Sensitive extractive spectrophotometric methods for the determination of nortriptyline hydrochloride in pharmaceutical formulations.
Misiuk, W; Tykocka, A, 2007
)
0.78
"In a multicentre part-randomised open-label design (the Genome Based Therapeutic Drugs for Depression (GENDEP) study) 811 adults with moderate to severe unipolar depression were allocated to flexible dosage escitalopram or nortriptyline for 12 weeks."( Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression.
Aitchison, KJ; Barreto, M; Dmitrzak-Weglarz, M; Elkin, A; Farmer, A; Giovannini, C; Hauser, J; Henigsberg, N; Jorgensen, L; Kalember, P; Landau, S; Maier, W; Marusic, A; McGuffin, P; Mors, O; Petrovic, A; Placentino, A; Rietschel, M; Schmael, C; Souery, D; Uher, R; Zobel, A, 2009
)
0.8
" A total of 796 adult patients with major depressive disorder who were treated with a flexible dosage of escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP) were included in the sample and provided data on suicidal ideation."( Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project.
Aitchison, KJ; Bonvicini, C; Craig, I; Farmer, AE; Gray, J; Gupta, B; Hauser, J; Henigsberg, N; Huezo-Diaz, P; Jorgensen, L; Kalember, P; Kapelski, P; Lewis, CM; Maier, W; Marusic, A; McGuffin, P; Mors, O; Perroud, N; Petrovic, A; Placentino, A; Rietschel, M; Schulze, TG; Smith, R; Souery, D; Uher, R; Zobel, A, 2009
)
0.56
"In a multicentre part-randomised open-label study, 811 adult patients with moderate to severe unipolar depression were allocated to flexible dosage of escitalopram or nortriptyline for 12 weeks."( Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial.
Aitchison, KJ; Campbell, D; Elkin, A; Farmer, AE; Giovannini, C; Gray, J; Gunasinghe, C; Gupta, B; Hauser, J; Henigsberg, N; Jorgensen, L; Maier, W; Marusic, A; McGuffin, P; Mors, O; Perroud, N; Placentino, A; Rietschel, M; Souery, D; Strohmaier, J; Szczepankiewicz, A; Uher, R; Zobel, A, 2009
)
0.78
" The actual dosing levels at the second treatment were compared with estimates based on HA."( Seizure threshold in a large sample: implications for stimulus dosing strategies in bilateral electroconvulsive therapy: a report from CORE.
Bailine, S; Braga, RJ; Fink, M; Husain, M; Kellner, C; Knapp, R; Malur, C; Mueller, M; O'Connor, K; Petrides, G; Rummans, T, 2009
)
0.35
"Among 811 adults with moderate-to-severe depression, melancholic, atypical, anxious and anxious-somatizing depression subtypes established at baseline were evaluated as predictors of outcome of treatment with flexible dosage of the SSRI escitalopram or the tricyclic antidepressant nortriptyline."( Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline.
Aitchison, KJ; Dernovsek, MZ; Farmer, A; Hauser, J; Henigsberg, N; Kalember, P; Maier, W; McGuffin, P; Mendlewicz, J; Mors, O; Placentino, A; Rietschel, M; Souery, D; Uher, R; Zobel, A, 2011
)
0.76
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"We tested nine symptom dimensions derived from a previously published factor analysis of depression rating scales as predictors of outcome in 811 adults with moderate to severe depression treated with flexibly dosed escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP)."( Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.
Aitchison, KJ; Bajs, M; Dernovsek, MZ; Farmer, A; Hauser, J; Henigsberg, N; Maier, W; McGuffin, P; Mors, O; Perlis, RH; Rietschel, M; Souery, D; Uher, R; Zobel, A, 2012
)
0.56
" Quantitative proteomic analyses were undertaken on hippocampal tissue from a study design that used two inbred mouse strains, two depressogenic protocols and a control condition, (maternal separation, chronic mild stress, control), two antidepressant drugs and two dosing protocols."( Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains.
Aitchinson, KJ; Binder, E; Campbell, J; Craig, I; Davies, M; Keers, R; Kuhn, K; Malki, K; McGuffin, P; Paya-Cano, J; Schalkwyk, LC; Selzer, S; Sluyter, F; Uher, R; Ward, M, 2012
)
0.38
"During an acute ECT phase, 319 patients were randomized to treatment with moderate dosage bilateral ECT or high-dosage right unilateral ECT."( Pharmacological strategies in the prevention of relapse after electroconvulsive therapy.
Cooper, T; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, PB; Sackeim, HA, 2013
)
0.39
" By study phase, Eight of 27 (30%) patients remitted with initial dosing of tranylcypromine up to 60 mg/d, 6/18 (33%) remitted with above PDR dosing of tranylcypromine up to 120 mg/d, and 1/6 (17%) to adding dextroamphetamine."( How treatable is refractory depression?
Deliyannides, DA; McGrath, PJ; Stewart, JW, 2014
)
0.4
" Data on QTc interval, age, gender, the type and daily dosage of TCAs, the medication period until the second ECG examination, and ECG findings were obtained from electronic medical charts."( Use of tricyclic antidepressants as analgesic adjuvants results in nonhazardous prolongation of the QTc interval.
Funai, Y; Funao, T; Hase, I; Ikenaga, K; Nishikawa, K; Takahashi, R, 2014
)
0.4
" The initial rate and fixed time methods have been successfully applied to the determination of nortriptyline hydrochloride in commercial dosage form."( Kinetic modelling for the assay of nortriptyline hydrochloride using potassium permanganate as oxidant.
Khan, S; Rahman, N, 2015
)
0.91
" Patients with deviant genotype (that is poor, intermediate or ultrarapid genotype) will be randomly allocated to an intervention group in which the genotype and dosing advice is communicated to the treating physician, or to a control group in which patients receive care as usual."( Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).
Berm, EJ; Boshuisen, M; Breuning, L; Brouwers, JR; Dhondt, T; Hak, E; Jansen, PA; Kok, RM; Maring, JG; Mulder, H; Postma, M; Risselada, AJ; van Marum, R; Venema, H; Vleugel, L; Voshaar, RC; Wilffert, B, 2015
)
0.63
"In this sample where antidepressant dosage is titrated using clinical judgement, P450 genotypes do not explain differences between patients in side effects with antidepressants."( Exploring the role of drug-metabolising enzymes in antidepressant side effects.
Aitchison, KJ; Craig, IW; Dernovšek, MZ; Dobson, RJ; Farmer, AE; Hauser, J; Henigsberg, N; Hodgson, K; Maier, W; McGuffin, P; Mors, O; Placentino, A; Rietschel, M; Souery, D; Tansey, KE; Uher, R, 2015
)
0.42
" We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d."( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015
)
0.42
" In the primary analysis, fluoxetine 40mg/day was equivalent to paroxetine dosage of 34."( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015
)
0.42
" Improvement from sub- or supratherapeutically dosed patients to correctly dosed patients was simulated, assuming that genotyping would prevent under- or overdosing of patients."( A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy.
Berm, EJ; Gout-Zwart, JJ; Luttjeboer, J; Postma, MJ; Wilffert, B, 2016
)
0.64
" Hence, a different dosing strategy is required among smoking and nonsmoking patients."( Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2.
Deckert, J; Hommers, LG; Menke, A; Samanski, L; Scherf-Clavel, M; Unterecker, S, 2019
)
0.51
" Therefore, in these cases, pharmacokinetic values derived from routine dosing should not be used to make clinical decisions (such as timing of discontinuation of sodium bicarbonate infusion)."( Delayed Cardiotoxicity From a Massive Nortriptyline Overdose Requiring Prolonged Treatment.
Eche, IM; Elsamadisi, P; Sclafani, A, 2020
)
0.83
"The pharmacokinetics of two fluoxetine capsulated dosage forms and two amitriptyline tablet forms after a single oral intake was studied in dogs and healthy volunteers."( Experimental and Clinical Pharmacokinetics of Fluoxetine and Amitriptyline: Comparative Analysis and Possible Methods of Extrapolation.
Gneushev, ET; Kondratenko, SN; Kukes, VG; Savelyeva, MI; Shikh, EV, 2019
)
0.51
" Genetic variation of the CYP2D6 isoenzyme can influence the optimal dosage needed for individual patients."( Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial).
Berm, EJJ; Breuning, L; Brouwers, JRBJ; Ditters, K; Hak, E; Jansen, PAF; Kok, RM; Maring, JG; Mulder, H; Nanninga, J; Oude Voshaar, RC; Postma, M; Risselada, AJ; Stek, M; van der Schans, J; van Marum, R; van Schaik, RHN; Vleugel, L; Wilffert, B,
)
0.36
" In the intervention arm (DG-I), the specific genotype accompanied by a standardized dosing recommendation based on the patients' genotype and the prescribed drug was directly communicated to the physician of the participant."( Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial).
Berm, EJJ; Breuning, L; Brouwers, JRBJ; Ditters, K; Hak, E; Jansen, PAF; Kok, RM; Maring, JG; Mulder, H; Nanninga, J; Oude Voshaar, RC; Postma, M; Risselada, AJ; Stek, M; van der Schans, J; van Marum, R; van Schaik, RHN; Vleugel, L; Wilffert, B,
)
0.36
"We aimed to examine the risk of cardiovascular adverse events by tricyclic antidepressant (TCA) dosage among patients with chronic pain."( Risk of cardiovascular events according to the tricyclic antidepressant dosage in patients with chronic pain: a retrospective cohort study.
Jeon, N; Jeong, KH; Jung, SY; Koo, H; Park, S; You, SH, 2023
)
0.91
" Especially for tricyclic antidepressants (TCAs), pharmacogenetics may be of interest because therapeutic plasma concentrations are well defined, identification of optimal dosing can be time consuming, and treatment is frequently accompanied by adverse effects."( Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial.
Aarnoutse, RE; Coenen, MJH; Donders, R; Grotenhuis, AJ; Janzing, JGE; Kievit, W; Mihaescu, R; Schellekens, AFA; Spijker, J; Ter Hark, SE; van der Meij, A; Vos, CF, 2023
)
0.91
"In the PIT group, the initial TCA dosage was based on CYP2D6 and CYP2C19 genotypes."( Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial.
Aarnoutse, RE; Coenen, MJH; Donders, R; Grotenhuis, AJ; Janzing, JGE; Kievit, W; Mihaescu, R; Schellekens, AFA; Spijker, J; Ter Hark, SE; van der Meij, A; Vos, CF, 2023
)
0.91
" These findings indicate that pharmacogenetics-informed dosing of TCAs can be safely applied and may be useful in personalizing treatment for patients with MDD."( Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial.
Aarnoutse, RE; Coenen, MJH; Donders, R; Grotenhuis, AJ; Janzing, JGE; Kievit, W; Mihaescu, R; Schellekens, AFA; Spijker, J; Ter Hark, SE; van der Meij, A; Vos, CF, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
drug metabolitenull
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
adrenergic uptake inhibitorAdrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
analgesicAn agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organic tricyclic compound
secondary amineA compound formally derived from ammonia by replacing two hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (106)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency223.44170.003245.467312,589.2998AID2517
dopamine D1 receptorHomo sapiens (human)Potency2.59290.00521.30228.1995AID624455
ATAD5 protein, partialHomo sapiens (human)Potency23.09990.004110.890331.5287AID493107
TDP1 proteinHomo sapiens (human)Potency24.84460.000811.382244.6684AID686978; AID686979
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.94330.001318.074339.8107AID926; AID938
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency18.99910.01237.983543.2770AID1645841
cytochrome P450 2D6Homo sapiens (human)Potency4.77240.00108.379861.1304AID1645840
67.9K proteinVaccinia virusPotency11.22020.00018.4406100.0000AID720580
arylsulfatase AHomo sapiens (human)Potency33.80781.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency31.62280.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency41.39990.016525.307841.3999AID602332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency8.44030.00207.533739.8107AID891
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency58.04790.01262.451825.0177AID485313
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency19.95260.316212.443531.6228AID902; AID924
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.31620.00255.840031.6228AID899
D(1A) dopamine receptorHomo sapiens (human)Potency7.98990.02245.944922.3872AID488981; AID488982; AID488983
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
huntingtin isoform 2Homo sapiens (human)Potency25.11890.000618.41981,122.0200AID1688
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency14.68920.00669.809418.4927AID1347050
flap endonuclease 1Homo sapiens (human)Potency3.76860.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency23.99110.00378.618923.2809AID2660; AID2666; AID2667; AID2668
gemininHomo sapiens (human)Potency29.85540.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency11.42390.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency14.21910.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.96840.00106.000935.4813AID943; AID944
lamin isoform A-delta10Homo sapiens (human)Potency0.14330.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency18.85410.316212.765731.6228AID881
Integrin beta-3Homo sapiens (human)Potency19.95260.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency19.95260.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency18.85410.00638.235039.8107AID881
D(1A) dopamine receptorSus scrofa (pig)Potency23.28090.00378.108123.2809AID2667
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency17.78280.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency1.99531.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency15.84890.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)0.01600.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.00820.00000.887110.0000AID625218
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)0.00320.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki0.00320.00322.28879.3160AID625207
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)0.34700.00001.23267.7930AID625152
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki0.12300.00000.690210.0000AID625152
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)0.09500.00001.15467.5858AID625154
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.01300.00000.79519.1201AID625154
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.17000.00040.629810.0000AID6418
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)0.02700.00010.99178.0000AID625155
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki0.02000.00000.72926.9183AID625155
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.36600.00001.44217.3470AID36031; AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.27500.00010.807410.0000AID625201
Cytochrome P450 2C8Homo sapiens (human)Ki49.90000.00180.38733.3000AID589253
Cytochrome P450 2D26Rattus norvegicus (Norway rat)IC50 (µMol)1.90000.09402.16285.6000AID54564
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)1.95000.00002.015110.0000AID240619; AID54564; AID54570; AID625249
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)0.08200.00001.403910.0000AID625151
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.02000.00000.59729.1201AID625151
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.17000.00040.908610.0000AID6418
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.04700.00001.23808.1590AID36031; AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.04300.00020.725710.0000AID625202
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)0.10150.00001.47257.8980AID36031; AID625203
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.03000.00030.483410.0000AID625203
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)1.01900.00031.38338.4000AID625190; AID6418
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki1.06800.00010.739610.0000AID625190
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)0.17100.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.03600.00000.54057.7600AID625153
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)0.53900.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki0.26900.00010.836310.0000AID625252
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.00320.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.00470.00031.465610.0000AID143642; AID625207
Histamine H2 receptorHomo sapiens (human)IC50 (µMol)2.33400.02202.298710.0000AID625270
Histamine H2 receptorHomo sapiens (human)Ki2.29500.00062.197310.0000AID625270
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)0.27300.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.13400.00000.360910.0000AID625200
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.05100.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.01500.00000.385510.0000AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.01600.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.00820.00010.954910.0000AID625218
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)1.01900.00051.48357.8000AID625190; AID6418
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki1.06800.00031.29679.2440AID625190
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)IC50 (µMol)0.17000.00311.73607.8000AID6418
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)IC50 (µMol)0.17000.00501.79627.8000AID6418
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.17000.00040.615610.0000AID6418
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)IC50 (µMol)0.17000.00501.50894.6000AID6418
Histamine H1 receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00000.00000.32271.2589AID87513
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.01300.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.00700.00000.70488.1930AID625222
Sodium- and chloride-dependent GABA transporter 1Mus musculus (house mouse)IC50 (µMol)389.02250.03712.19228.5114AID1195448
Sodium- and chloride-dependent GABA transporter 2Mus musculus (house mouse)IC50 (µMol)269.57651.41255.26838.1283AID1195450
Sodium- and chloride-dependent GABA transporter 3Mus musculus (house mouse)IC50 (µMol)250.09451.54883.67618.1283AID1195451
Sodium- and chloride-dependent betaine transporterMus musculus (house mouse)IC50 (µMol)170.41200.18003.188010.0000AID1195449
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)IC50 (µMol)0.17000.00501.42824.6000AID6418
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)3.00000.00002.398310.0000AID625247
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)IC50 (µMol)0.17000.00501.35984.6000AID6418
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)IC50 (µMol)0.17000.00501.35984.6000AID6418
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)0.05000.00000.44365.1768AID625269
Histamine H1 receptorHomo sapiens (human)Ki0.00590.00000.511010.0000AID625269
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)0.17900.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.06100.00000.602010.0000AID625254
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)IC50 (µMol)0.17000.00021.13514.6000AID6418
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.13600.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.08600.00030.769310.0000AID625217
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00000.00001.819410.0000AID36031
Histamine H2 receptorCavia porcellus (domestic guinea pig)IC50 (µMol)7.00000.00402.15557.2000AID87880
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)0.55400.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.23550.00020.522910.0000AID625221; AID691260
Voltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)IC50 (µMol)10.00000.04004.113710.0000AID1850268
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)1.67800.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki1.33300.00021.11158.0280AID625256
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)IC50 (µMol)0.17000.00501.35524.6000AID6418
Cytochrome P450 2D4Rattus norvegicus (Norway rat)IC50 (µMol)19.30001.70001.70001.7000AID54566
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)IC50 (µMol)0.17000.00041.17424.6000AID6418
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H2 receptorCavia porcellus (domestic guinea pig)K0.50.01510.00010.40364.8000AID88009
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (409)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
gastric acid secretionHistamine H2 receptorHomo sapiens (human)
immune responseHistamine H2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H2 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
modulation of chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
response to amyloid-betaVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (128)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
histamine receptor activityHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H2 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H2 receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
amyloid-beta bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
protein bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
ATP bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (89)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
synapseHistamine H2 receptorHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
dendriteHistamine H2 receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
synapseVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
neuronal cell bodyVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (246)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID186207Log (1/ED50*10e-3) was measured as histamine releasing activity in rat mast cells. c1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID298032Acid dissociation constant, pKa of the compound2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID54565Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D3 expressed in Saccharomyces cerevisiae2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID6418Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID179753In vitro inhibition of the accumulation of (-)-[3H]Norepinephrine in synaptosomes from the rat brain cortex1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID23973Partition coefficient (logD, measured by HPLC, log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID349947Antinociceptive activity against formalin-induced pain in BALB/c mouse assessed paw licking, biting or shaking at 0.5 mg/kg, po equimolar dose of nortriptyline administered 2 hrs before formalin challenge measured after 0 to 5 mins relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID25866Protonation constant of the compound.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1195449Inhibition of mouse mGAT2 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure activity relationship of selective GABA uptake inhibitors.
AID1636450Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 87 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NAD2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID143642Compound was evaluated for its binding affinity towards human NET (norepinephrine) transporter2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26296Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID54566Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D4 expressed in Saccharomyces cerevisiae2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID1195448Inhibition of mouse mGAT1 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure activity relationship of selective GABA uptake inhibitors.
AID1220559Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID22538Half life period is estimated1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID240619Inhibitory concentration against cytochrome P450 2D62004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID349962Anxiolytic activity in BALB/c mouse assessed as velocity at 5 mg/kg, po after 90 mins by open-field test (RVb= 7.07+/-0.51 cm/s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID87513Compound tested for its inhibitory activity against Histamine H1 receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID349950Antinociceptive activity against formalin-induced pain in BALB/c mouse assessed paw licking, biting or shaking at 5 mg/kg, po equimolar dose of nortriptyline administered 2 hrs before formalin challenge measured after 25 to 35 mins relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID349974Anxiolytic activity in BALB/c mouse assessed as immobility at 15 mg/kg, po after 90 mins by open-field test (RVb= 458.4+/-41 s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID147591Compound was tested for its inhibitory activity against Noradrenaline receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID23960logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1636392Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 87.2 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID349926Antinociceptive activity in BALB/c mouse assessed as decrease in paw withdrawal latency at 4.5 mg/kg, po after 240 mins by hot plate method2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID23968logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID395324Lipophilicity, log D at pH 7.4 by liquid chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1864494Inhibition of human OCT3 overexpressed in HEK293 cells assessed as intracellularly accumulation of ASP+ at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID349963Anxiolytic activity in BALB/c mouse assessed as velocity at 15 mg/kg, po after 90 mins by open-field test (RVb= 7.07+/-0.51 cm/s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID349961Anxiolytic activity in BALB/c mouse assessed as velocity at 1 mg/kg, po after 90 mins by open-field test (RVb= 7.07+/-0.51 cm/s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID349972Anxiolytic activity in BALB/c mouse assessed as immobility at 1 mg/kg, po after 90 mins by open-field test (RVb= 458.4+/-41 s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID232042Selectivity expressed as ratio between NE and 5-HT uptake inhibition in rat synaptosomes1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID58618Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing 50% reduction in ectopic rate; Ectopic rate was not reduced by 50% in any experiment1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Antiarrhythmic activity of amitriptyline analogues in conscious dogs after myocardial infarction: cyproheptadinium methiodide.
AID116717Acute cytotoxicity was evaluated as LD50 in mice (ip)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1353624Antiallodynic activity in C57BL/6J mouse model of sciatic nerve ligation-induced neuropathic pain assessed as increase in paw withdrawal latency time at 5 mg/kg, ip bid for 17 consecutive days starting from 2 to 3 weeks post surgery measured on day 11 dur2018European journal of medicinal chemistry, Mar-10, Volume: 147Phenylpyridine-2-ylguanidines and rigid mimetics as novel inhibitors of TNFα overproduction: Beneficial action in models of neuropathic pain and of acute lung inflammation.
AID1215121Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID26294Partition coefficient (logD) (HPLC)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1220555Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID23970logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID26538log K was measured potentiometrically in Brij35 medium1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID298031Lipophilicity, log D at pH7.42007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID22432Volume of distribution in the plasma fluid was determined1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID349973Anxiolytic activity in BALB/c mouse assessed as immobility at 5 mg/kg, po after 90 mins by open-field test (RVb= 458.4+/-41 s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID88009Displacement of [3H](-)-trans-H2-PAT from histamine H2 PAT binding site by competition binding assay.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID1195451Inhibition of mouse mGAT4 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure activity relationship of selective GABA uptake inhibitors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID349999Anxiolytic activity in BALB/c mouse assessed as distance moved at 5 mg/kg, po after 90 mins by open-field test (RVb= 8485+/-610 cm)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID214496Percent Inhibition of trypanothione reductase activity at 5.7 uM concentration1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
A virtual screening approach applied to the search for trypanothione reductase inhibitors.
AID1210014Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1353623Antiallodynic activity in C57BL/6J mouse model of sciatic nerve ligation-induced neuropathic pain assessed as increase in paw withdrawal latency time at 1 mg/kg, ip bid for 17 consecutive days starting from 2 to 3 weeks post surgery by Von Frey test2018European journal of medicinal chemistry, Mar-10, Volume: 147Phenylpyridine-2-ylguanidines and rigid mimetics as novel inhibitors of TNFα overproduction: Beneficial action in models of neuropathic pain and of acute lung inflammation.
AID87880Inhibitory activity against brain adenylate cyclase Histamine H2 receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID624696Mechanism based inhibition of rat cytochrome P450 CYP2C11 measured by 2-alpha and 16-alpha hydroxylation of testosterone2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1215122Percentage unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID311933Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1195450Inhibition of mouse mGAT3 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure activity relationship of selective GABA uptake inhibitors.
AID132432Ex vivo inhibition of the accumulation of (-)-[3H]-5-HT in slices from the middle part of the mouse brain. (i.p.)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID589253Mechanism based inhibition of human cytochrome P450 2C8 measured by paclitaxel hydroxylation using a recombinant system2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID349983Antiinflammatory activity against formalin-induced BALB/c mouse skin assessed as reduction in TNFalpha level at to 0.5 mg/kg, po2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID289402Displacement of [3H]leucine from Aquifex aeolicus His-LeuT expressed in Escherichia coli by scintillation proximity assay2007Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1220560Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1210013Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1215126Ratio of fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID1220557Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID349925Antinociceptive activity in BALB/c mouse assessed as decrease in paw withdrawal latency at 0.25 mg/kg, po after 240 mins by hot plate method2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID349998Anxiolytic activity in BALB/c mouse assessed as distance moved at 15 mg/kg, po after 90 mins by open-field test (RVb= 8485+/-610 cm)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID114156Antidepressant activity was evaluated by measuring its ability to antagonize RO 4-1284-induced hypothermia in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID132433Ex vivo inhibition of the accumulation of (-)-[3H]Norepinephrine in slices from the middle part of the mouse brain. (i.p.)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID54562Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D1 expressed in Saccharomyces cerevisiae2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1366320Antiplasmodial activity against Plasmodium falciparum K1 at 0.002 to 100 ug/ml by serial drug dilution assay2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Astemizole analogues with reduced hERG inhibition as potent antimalarial compounds.
AID34292Compound was tested for its binding affinity towards brain (Hippocampus) Adenylate cyclase1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID624659Inhibition of morphine (6-O-glucuronidation) glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID349944Antinociceptive activity against formalin-induced pain in BALB/c mouse assessed paw licking, biting or shaking at 0.5 mg/kg, po administered 2 hrs before formalin challenge measured after 25 to 35 mins relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID349945Antinociceptive activity against formalin-induced pain in BALB/c mouse assessed paw licking, biting or shaking at 5 mg/kg, po administered 2 hrs before formalin challenge measured after 0 to 5 mins relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID36031Compound was tested for its inhibitory activity against Alpha-1 adrenergic receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID23966logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID23964logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID349943Antinociceptive activity against formalin-induced pain in BALB/c mouse assessed paw licking, biting or shaking at 0.5 mg/kg, po administered 2 hrs before formalin challenge measured after 0 to 5 mins relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID34293Compound was tested for its binding affinity towards brain (neocortex) Adenylate cyclase1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID26295Partition coefficient (logD) (HPLC)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID54564Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D2 expressed in Saccharomyces cerevisiae2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
AID54570Inhibition of MAMC O-dealkylation mediated by human Cytochrome P450 2D6 expressed in human lymphoblastoid cell line2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
AID26396Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID179752In vitro inhibition of the accumulation of (-)-[3H]-5-HT in synaptosomes from the rat brain cortex1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID214495Percent Inhibition of trypanothione reductase activity at 28.5 uM concentration1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
A virtual screening approach applied to the search for trypanothione reductase inhibitors.
AID15708Plasma clearance for the compound was determined.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1220558Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID349991Antiinflammatory activity against gamma carrageenan-induced paw edema in Wistar rat assessed as paw volume at 5 mg/kg, po equimolar dose of nortriptyline administered 2 hrs before carrageenan challenge relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID23708Partition coefficient (logP)1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID23971logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID114157Antidepressant activity was evaluated by measuring its ability to antagonize reserpine-induced ptosis in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID232041Selectivity expressed as ratio between NE and 5-HT uptake inhibition in mouse brain slices1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID349927Antinociceptive activity in BALB/c mouse assessed as decrease in paw withdrawal latency at 0.5 mg/kg, po equimolar dose of nortriptyline after 240 mins by hot plate method2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID395327Dissociation constant, pKa by capillary electrophoresis2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1220556Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID58620Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing for conversion to sinus rhythm; Conversion to sinus rhythm did not occur1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Antiarrhythmic activity of amitriptyline analogues in conscious dogs after myocardial infarction: cyproheptadinium methiodide.
AID1220554Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID214497Percent Inhibition of trypanothione reductase activity at 57 uM concentration1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
A virtual screening approach applied to the search for trypanothione reductase inhibitors.
AID350000Anxiolytic activity in BALB/c mouse assessed as distance moved at 1 mg/kg, po after 90 mins by open-field test (RVb= 8485+/-610 cm)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID132672In vitro inhibition of the accumulation of (-)-[3H]Norepinephrine in slices from the middle part of the mouse brain.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID349929Antinociceptive activity in BALB/c mouse assessed as decrease in paw withdrawal latency at 4.5 mg/kg, po equimolar dose of nortriptyline after 240 mins by hot plate method2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID349948Antinociceptive activity against formalin-induced pain in BALB/c mouse assessed paw licking, biting or shaking at 0.5 mg/kg, po equimolar dose of nortriptyline administered 2 hrs before formalin challenge measured after 25 to 35 mins relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID132671In vitro inhibition of the accumulation of (-)-[3H]-5-HT in slices from the middle part of the mouse brain.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
AID349946Antinociceptive activity against formalin-induced pain in BALB/c mouse assessed paw licking, biting or shaking at 5 mg/kg, po administered 2 hrs before formalin challenge measured after 25 to 35 mins relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID349949Antinociceptive activity against formalin-induced pain in BALB/c mouse assessed paw licking, biting or shaking at 5 mg/kg, po equimolar dose of nortriptyline administered 2 hrs before formalin challenge measured after 0 to 5 mins relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID680105TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse2000Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Apr, Volume: 22, Issue:4
Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption.
AID189474Apparent partition coefficient was measured as histamine releasing activity in rat mast cells.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID23961logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID26300log P values determined at pH 7.41999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1850268Inhibition of endogenous human CaV2.2 in human SH-SY5Y cells in presence of nifedipine by Calcium 4 dye based calcium influx fluorescence-imaging assay2022RSC medicinal chemistry, Feb-23, Volume: 13, Issue:2
Inhibition of N-type calcium ion channels by tricyclic antidepressants - experimental and theoretical justification for their use for neuropathic pain.
AID691260Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells after 1.5 hrs by liquid scintillation counting2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.
AID1636502Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 74 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NAD2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID349928Antinociceptive activity in BALB/c mouse assessed as decrease in paw withdrawal latency at 0.25 mg/kg, po equimolar dose of nortriptyline after 240 mins by hot plate method2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID624658Inhibition of morphine (3-O-glucuronidation) glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346971Human NET (Monoamine transporter subfamily)2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors.
AID1346501Mouse Kir3.2 (Inwardly rectifying potassium channels)2004Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Oct, Volume: 29, Issue:10
Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
AID1346535Mouse Kir3.4 (Inwardly rectifying potassium channels)2004Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Oct, Volume: 29, Issue:10
Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
AID1346548Human Kir4.1 (Inwardly rectifying potassium channels)2007The Journal of pharmacology and experimental therapeutics, Feb, Volume: 320, Issue:2
Inhibition of astroglial inwardly rectifying Kir4.1 channels by a tricyclic antidepressant, nortriptyline.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,142)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901027 (47.95)18.7374
1990's370 (17.27)18.2507
2000's375 (17.51)29.6817
2010's298 (13.91)24.3611
2020's72 (3.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 119.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index119.87 (24.57)
Research Supply Index7.94 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index225.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (119.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials517 (22.59%)5.53%
Reviews154 (6.73%)6.00%
Case Studies221 (9.65%)4.05%
Observational3 (0.13%)0.25%
Other1,394 (60.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (46)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients [NCT01352572]300 participants (Anticipated)Interventional2002-01-31Active, not recruiting
Randomized, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Conservative Management With Medications and Physical Therapy in Patients With Cervical Radiculopathy [NCT01144923]169 participants (Actual)Interventional2010-06-30Completed
[NCT01268709]Phase 20 participants InterventionalCompleted
Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype [NCT01352559]1,000 participants (Anticipated)Interventional2001-11-30Active, not recruiting
Tailored Treatment of Functional Dyspepsia With Nortriptyline: a Multi-center Double-blind Placebo-controlled Trial [NCT03652571]Phase 3154 participants (Anticipated)Interventional2018-09-01Recruiting
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene [NCT02237937]Phase 480 participants (Anticipated)Interventional2011-09-30Recruiting
Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments [NCT03844412]Phase 2400 participants (Anticipated)Interventional2019-11-04Recruiting
Effect of Nortriptyline in the Cortical Representation of Heartburn in Patients With Nonerosive Reflux Disease [NCT01065649]Phase 320 participants (Actual)Interventional2010-01-31Completed
Predict Antidepressant Responsiveness Using Pharmacogenomics [NCT01228357]1,000 participants (Anticipated)Interventional2003-02-28Recruiting
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial [NCT01305707]Phase 4104 participants (Actual)Interventional2009-07-31Terminated(stopped due to Difficulties in recruiting)
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients [NCT00817375]1,000 participants (Anticipated)Interventional2003-02-28Recruiting
RCT of Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro RCT) [NCT05531591]Phase 4600 participants (Anticipated)Interventional2019-08-01Active, not recruiting
A Phase I, Single-Center, Randomized, Vehicle-Controlled Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers [NCT00721331]Phase 120 participants (Anticipated)Interventional2008-07-31Completed
Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI [NCT00539240]Phase 2/Phase 3236 participants (Actual)Interventional2006-04-30Completed
A Single-Center, Randomized, Blinded, Vehicle- Controlled Exploratory Study to Assess the Activity of CRx-197 in Subjects With Plaque Psoriasis [NCT00796211]Phase 220 participants (Anticipated)Interventional2008-11-30Completed
Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia [NCT00547703]5 participants (Actual)Interventional2008-02-29Terminated(stopped due to Not enough participants - only 5 since the study started)
Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness [NCT00817011]1,000 participants (Anticipated)Interventional2006-04-30Recruiting
A Single-Center, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Activity of CRx-191 in Reducing the Psoriatic Infiltrate Band Thickness in Plaque Psoriasis [NCT00557739]Phase 220 participants (Anticipated)Interventional2007-11-30Completed
Adapting Marital Therapy in Older Adults With Depression [NCT00612807]Phase 1/Phase 242 participants (Actual)Interventional2006-07-31Completed
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults [NCT02960763]Phase 4742 participants (Actual)Interventional2017-02-24Completed
Continuation ECT Vs Pharmacotherapy--Efficacy And Safety [NCT00000375]Phase 40 participants Interventional1997-02-28Completed
Antidepressant Treatment of Melancholia in Late :Ife [NCT00000378]Phase 4110 participants (Actual)Interventional1997-07-31Completed
Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation [NCT00018148]Phase 2158 participants (Actual)Interventional1998-04-30Completed
A Phase I, Single-Center, Randomized, Vehicle and Active-Controlled Study to Assess and Compare the Atrophy-Causing Potential of Topical CRx-191 Formulations in Healthy Volunteers [NCT00544687]Phase 120 participants (Actual)Interventional2007-09-30Completed
Relapse Prevention in Patients With a Major Depressive Episode Treated With Electroconvulsive Treatment Using a Fixed Dose Range of Escitalopram Compared to a Fixed Dose of Nortriptyline (DUAG-7) A Randomised Controlled 6 Month Double-blind Study [NCT00660062]Phase 447 participants (Actual)Interventional2009-08-31Terminated(stopped due to Slow inclusion)
A Phase 1 Study of Weekly Paclitaxel and Nortriptyline for Relapsed Small Cell Carcinoma [NCT02881125]Phase 12 participants (Actual)Interventional2016-11-03Completed
Treatment of Meniere's Disease With Nortriptyline-Topiramate Stepwise Regimen: A Randomized Double-Blinded Clinical Trial [NCT05582837]Phase 4100 participants (Anticipated)Interventional2022-08-01Recruiting
Morphine, Nortriptyline and Their Combination in Sciatica Treatment [NCT00009672]Phase 280 participants Interventional2001-01-30Completed
Optimization of Electroconvulsive Therapy [NCT00045916]Phase 4340 participants (Actual)Interventional2001-02-28Completed
Sequenced Treatment Alternatives to Relieve Depression [NCT00021528]Phase 44,000 participants Interventional2001-07-31Completed
Treatment for Post-concussive Headache: A Randomized, Placebo-controlled, Double Blinded Trial [NCT04226365]Phase 48 participants (Actual)Interventional2020-02-15Active, not recruiting
Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG) [NCT00765895]Phase 3130 participants (Actual)Interventional2009-01-31Completed
Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI. [NCT00251732]Phase 4150 participants (Actual)Interventional2005-03-31Completed
Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Major Depression Through Resources Available in Brazilian Public Health [NCT02901249]Phase 468 participants (Actual)Interventional2010-05-31Completed
Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode [NCT02918097]Phase 478 participants (Actual)Interventional2010-05-31Completed
Treatment of Depression in Patients With Parkinson's Disease [NCT00062738]Phase 252 participants (Actual)Interventional2003-06-30Completed
[NCT00004390]Phase 3120 participants Interventional1995-02-28Completed
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]74 participants (Anticipated)Interventional2013-04-30Recruiting
Pain Management in Temporomandibular Joint Disorders [NCT00066937]Phase 2140 participants (Actual)Interventional2002-11-30Completed
A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease [NCT03652870]Phase 352 participants (Actual)Interventional2021-03-05Completed
Maintenance Therapies in Late-Life Depression [NCT00000377]0 participants Interventional1989-03-31Completed
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS) [NCT02260388]Phase 4402 participants (Actual)Interventional2014-10-31Completed
Treatment of Tinnitus With Migraine Medications: A Randomized Clinical Trial [NCT04404439]Phase 4150 participants (Anticipated)Interventional2019-09-26Recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis [NCT01943435]259 participants (Actual)Interventional2013-11-20Completed
A Prospective Randomized Cross-over Trial of Nortryptyline and Topiramate in the Initial Treatment of Vestibular Migraine. [NCT02169830]35 participants (Actual)Interventional2014-08-22Terminated(stopped due to Lack of enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00000378 (1) [back to overview]HAMILTON Rating Scale for DEPRESSION Range
NCT00062738 (2) [back to overview]Hamilton Depression Scale
NCT00062738 (2) [back to overview]Percent Responders
NCT00066937 (4) [back to overview]Average Pain
NCT00066937 (4) [back to overview]Change in Pain-related Interference
NCT00066937 (4) [back to overview]Mental Health as Assessed by the Short Form 36 Healthy Survey
NCT00066937 (4) [back to overview]Worst Pain
NCT00539240 (4) [back to overview]Acid Regurgitation, Number of Days in Week Symptoms Intensity Score < 3 (Better)
NCT00539240 (4) [back to overview]Daytime Heartburn, Number of Days in Week Symptoms Intensity Score < 3 (Better)
NCT00539240 (4) [back to overview]Health Related Quality of Life
NCT00539240 (4) [back to overview]Nighttime Heartburn, Number of Days in Week Symptom Activity Score <3 (Better) in Week 6 Compared to Baseline
NCT00547703 (1) [back to overview]Question on Whether Patient Has Had Adequate Relief of Abdominal Pain or Discomfort Reported by a Simple Yes or no Answer.
NCT00612807 (2) [back to overview]Dyadic Adjustment Scale (DAS)
NCT00612807 (2) [back to overview]Hamilton Depression Rating Scale (HDRS)
NCT00765895 (1) [back to overview]Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits
NCT01943435 (3) [back to overview]Self Paced Walking Test (SPWT)
NCT01943435 (3) [back to overview]Sense Wear Armband
NCT01943435 (3) [back to overview]Swiss Spinal Stenosis (SSS) Questionnaire Score
NCT02260388 (4) [back to overview]PROMIS Fatigue Short Form v1.0 8a
NCT02260388 (4) [back to overview]PROMIS Pain Interference Short Form v1.0 8a T Score
NCT02260388 (4) [back to overview]PROMIS Sleep Disturbance Short Form v1.0 8a
NCT02260388 (4) [back to overview]SF12 Health Composite Scores
NCT02901249 (3) [back to overview]Number of Participants With Remission to Treatment
NCT02901249 (3) [back to overview]Number of Participants With Response to Treatment
NCT02901249 (3) [back to overview]Quality of Life -WHOQOL Intrument Scores
NCT02918097 (3) [back to overview]"Number of Participants With Response to Treatment"
NCT02918097 (3) [back to overview]Number of Participants With Remission to Treatment
NCT02918097 (3) [back to overview]Quality of Life Instrument Scores
NCT02960763 (3) [back to overview]Number of Participants With Remission From Depression
NCT02960763 (3) [back to overview]Serious Adverse Events
NCT02960763 (3) [back to overview]Psychological Well-Being

HAMILTON Rating Scale for DEPRESSION Range

Hamilton scale range 0-40, values below 7 are considered normal. the higher the number the more severe the depression weekly assessments, The primary outcome is a comparison of the baseline Hamilton to the 12 week measurement (NCT00000378)
Timeframe: BASELINE COMPARED TO 12 WEEK MEASUREMENT

,
Interventionunits on a scale (Mean)
BASELINE12 WEEK DATA
Nortriptyline27.18.4
Sertaline27.310.7

[back to top]

Hamilton Depression Scale

total score on HDRS (0-54 higher score is worse) (NCT00062738)
Timeframe: 8 weeks

Interventionunits on a scale (Least Squares Mean)
Nortriptyline10.84
Paroxetine12.45
Placebo15.81

[back to top]

Percent Responders

Percent of patients who had a 50% decrease in total HDRS at 8 weeks (NCT00062738)
Timeframe: 8 weeks

Interventionpercent of patients who were responders (Number)
Nortriptyline53
Paroxetine11
Placebo24

[back to top]

Average Pain

0 (no pain) to 10 (pain as bad as could be) rating of average pain during the past week; higher scores indicate greater pain (NCT00066937)
Timeframe: baseline, post-treatment, 3 months, 6 months

,,,
Interventionunits on a scale (Mean)
baselinepost treatment3 months6 months
Benztropine Oral Product/CBT4.42.72.42.0
Benztropine Oral Product/Disease MGT5.02.82.52.2
Nortriptyline Oral Capsule/CBT4.72.82.12.0
Nortriptyline Oral Capsule/Disease MGT4.52.02.21.4

[back to top] [back to top]

Mental Health as Assessed by the Short Form 36 Healthy Survey

The Mental Health Component score from the Short Form (36) Health Survey, which is a 36-item, patient-reported survey of patient health. The mental health component score is calculated from responses to the general health, mental health, vitality, physical and emotional role limitations, and social functioning subscales, with higher scores indicating better mental health. The scale ranges from zero (equivalent to maximum disability) to 100 (no disability). (NCT00066937)
Timeframe: baseline, post-treatment, 3 months, 6 months

,,,
Interventionunits on a scale (Mean)
baselinepost-treatment3 months6 months
Benztropine Oral Product/CBT49.248.450.253.3
Benztropine Oral Product/Disease MGT48.053.353.853.6
Nortriptyline Oral Capsule/CBT50.550.851.552.2
Nortriptyline Oral Capsule/Disease MGT51.252.652.652.3

[back to top]

Worst Pain

0 (no pain) to 10 (pain as bad as could be) rating of worst pain during the past week (NCT00066937)
Timeframe: baseline, post-treatment, 3 months, 6 months

,,,
Interventionunits on a scale (Mean)
baselinepost-treatment3 months6 months
Benztropine Oral Product/CBT6.14.13.33.1
Benztropine Oral Product/Disease MGT7.24.44.13.4
Nortriptyline Oral Capsule/CBT6.74.03.63.3
Nortriptyline Oral Capsule/Disease MGT6.33.23.42.7

[back to top]

Acid Regurgitation, Number of Days in Week Symptoms Intensity Score < 3 (Better)

the number of days with Symptom Intensity Score < 3 (better) for acid regurgitation during week 6 as compared to baseline (NCT00539240)
Timeframe: Symptom control after 6 weeks of treatment

Interventiondays (Mean)
Arm 16.7
Arm 25.9
Arm 36.3

[back to top]

Daytime Heartburn, Number of Days in Week Symptoms Intensity Score < 3 (Better)

the number of days with Symptom Intensity Score < 3 (better) for daytime heartburn during week 6 as compared to baseline (NCT00539240)
Timeframe: Symptom control after 6 weeks of treatment

Interventiondays (Mean)
Arm 16.6
Arm 25.9
Arm 36.1

[back to top] [back to top]

Nighttime Heartburn, Number of Days in Week Symptom Activity Score <3 (Better) in Week 6 Compared to Baseline

the number of days with Symptom Intensity Score < 3 (better) for nighttime heartburn during week 6 as compared to baseline (NCT00539240)
Timeframe: Symptom control after 6 weeks of treatment

Interventiondays (Mean)
Arm 16.6
Arm 25.8
Arm 36.0

[back to top]

Question on Whether Patient Has Had Adequate Relief of Abdominal Pain or Discomfort Reported by a Simple Yes or no Answer.

Patient would answer yes or no to a simple question asking whether they had adequate relief of abdominal pain or discomfort. This was measured at weeks 2,4 and 8 of the study but only week 8 was reported. What is being reported is the number of participants who answered yes. (NCT00547703)
Timeframe: 8 weeks

Interventionparticipants (Number)
Nortriptyline2
Placebo1

[back to top]

Dyadic Adjustment Scale (DAS)

The DAS is a self-report measure of marital adjustment that includes questions about agreement on lifestyle and household decisions, level of conflict, level of cooperation, and affection. Scores range from 0 to 151, with higher scores representing better relationship functioning. (NCT00612807)
Timeframe: pre-treatment, monthly, post-treatment, 6 month follow-up

,
InterventionScore on DAS measure (Mean)
Baseline assessment (Depressed spouse)Post-test assessment (Depressed spouse)Follow-up assessment (Depressed spouse)Baseline assessment (Non-depressed spouse)Post-test assessment (Non-depressed spouse)Follow-up assessment (Non-depressed spouse)
Semi-weekly Medication Management72.1484.1789.6791.093.33104.17
Semi-weekly Medication Management + Weekly Marital Therapy84.4392.2791.0788.2997.5798.31

[back to top]

Hamilton Depression Rating Scale (HDRS)

The HDRS is a semi-structured interview administered by a trained independent evaluator, and used for rating the severity of depressive symptoms. Scores range from 0 to 50, with higher scores indicating greater severity of depression. (NCT00612807)
Timeframe: pre-treatment, monthly, post-treatment, 6 month follow-up

,
InterventionScore on HDRS (Mean)
Baseline assessment (Depressed spouse)Post-test assessment (Depressed spouse)Follow-up assessment (Depressed spouse)Baseline assessment (Non-depressed spouse)Post-test assessment (Non-depressed spouse)Follow-up assessment (Non-depressed spouse)
Semi-weekly Medication Management17.865.009.175.145.333.83
Semi-weekly Medication Management + Weekly Marital Therapy19.07.298.148.863.295.71

[back to top]

Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits

A decrease from the baseline Gastroparesis Cardinal Symptom Index (GCSI) score (sum of the 9 individual symptom scores) of at least 50% on any two consecutive follow-up visits during the 15 week treatment period with maximum tolerated study drug dose. The total score ranges from 0-45 with higher scores indicating greater symptom severity. (NCT00765895)
Timeframe: at end of treatment, 15 weeks from baseline assessment

Interventionparticipants (Number)
Nortriptyline15
Placebo14

[back to top]

Self Paced Walking Test (SPWT)

Our primary aim also included a performance-based outcome measure, which was the distance walked during the SPWT. The analysis was a comparison of between-group changes in SPWT between baseline and 8 weeks. The Self-Paced Walking Test (SPWT) is a validated objective measure of a patient's walking capacity, which is performed on a level walking surface. The patient is instructed to walk at their own pace and to stop when the symptoms are troublesome enough that s/he needs to sit down to rest. The total time and total distance walked are measured by the research assistant. Our unit of measure was the total distance walked, expressed in meters. (NCT01943435)
Timeframe: Primary end-point was 8 weeks ( 2 weeks after 6 week intervention is completed).

Interventionmeters (Mean)
Medical Care130.5
Group Exercise219.2
Manual Therapy and Exercise267.8

[back to top]

Sense Wear Armband

Our secondary aim was to measure the change in physical activity between baseline and 8 weeks using the Sense Wear armband (SWA). The outcome measure was the average number of minutes spent daily performing physical activities >1.5 metabolic equivalents (METs).The SWA is a small device that collects information from multiple sensors: a triaxial accelerometer, heat flux, skin temperature, and galvanic signal. The information is integrated and processed by software using proprietary algorithms utilizing subjects' demographic characteristics (gender, age, height, and weight) to provide minute-by-minute estimates of physical activity. The SWA has shown good reliability and validity. The research participants in our study will wear the SWA for a week before and after they complete the treatment interventions. (NCT01943435)
Timeframe: Primary End-Point was 8 weeks ( 2 weeks after completion of 6-week intervention).

Interventionminutes per day (Mean)
Medical Care-23.1
Group Exercise4.3
Manual Therapy and Exercise-6.0

[back to top]

Swiss Spinal Stenosis (SSS) Questionnaire Score

Our primary aim included a primary outcome measure of self-reported pain/function, which was the change in SSS total score between baseline and 8 weeks. The Swiss Spinal Stenosis Questionnaire (SSS) is a validated 12-item condition-specific instrument for patients with lumbar spinal stenosis. It provides a patient self-report measure of pain and physical function. Higher scores represent worse symptoms and less physical function. The 12-item SSS total score range is 12-55. For our analysis, we compared the change in the 12-item Total score from baseline to 8 weeks. (NCT01943435)
Timeframe: Primary End-Point was 8 weeks ( 2 weeks after completion of 6-week intervention).

Interventionunits on a scale (Mean)
Medical Care-2.0
Group Exercise-1.7
Manual Therapy and Exercise-4.1

[back to top]

PROMIS Fatigue Short Form v1.0 8a

"Higher scores for fatigue represents worse outcome (more fatigue). T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 Weeks

InterventionT-Score (Mean)
Nortriptyline53.6
Duloxetine55.4
Pregabalin56.7
Mexiletine51.6

[back to top]

PROMIS Pain Interference Short Form v1.0 8a T Score

"Higher scores for pain interference represents worse outcome (more pain interference) T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 weeks

InterventionT-Score (Mean)
Nortriptyline56.4
Duloxetine56.5
Pregabalin60.0
Mexiletine54.5

[back to top]

PROMIS Sleep Disturbance Short Form v1.0 8a

"Higher scores for sleep disturbance represents worse outcome (more sleep disturbance).~T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population.~Higher scores equals more of the concept being measured" (NCT02260388)
Timeframe: 12 weeks

InterventionT-Score (Mean)
Nortriptyline58.9
Duloxetine58.9
Pregabalin58.3
Mexiletine59.1

[back to top]

SF12 Health Composite Scores

"SF-12v2® Health Survey Standard The Optum™ SF-12v2® Health Survey is a shorter version of the SF-36v2® Health Survey that uses just 12 questions to measure functional health and well-being from the patient's point of view.~Survey provides psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores.~Scores are calibrated so that 50 is the average score or norm, standard deviation = 10.~Higher scores indicate better health for both mental and physical component summary scores." (NCT02260388)
Timeframe: 12 weeks

,,,
InterventionNorm-Based Standardization Score (Mean)
Mental Component ScorePhysical Component Score
Duloxetine50.942.1
Mexiletine51.343.7
Nortriptyline51.042.8
Pregabalin47.240.0

[back to top]

Number of Participants With Remission to Treatment

The remission outcome was established as obtaining three consecutive scores of values considered asymptomatic in the Hamilton Rating Scale for Depression (HRSD <7 points) . The subjects that were asymptomatic for at least 6-8 month were considered to be in remission, according to the criteria for partial and complete remission in the DSM-IV. (NCT02901249)
Timeframe: 8 months

InterventionParticipants (Count of Participants)
Sertraline32

[back to top]

Number of Participants With Response to Treatment

Response to treatment was defined as a 50% reduction from baseline scores in Hamilton Rating Scale for Depression (HRSD). The HRSD is abbreviated version, consists of 17 items. The cutoff points are: 7-17 for mild depression,18-24 for moderate depression, and 25 or more for severe depression . (NCT02901249)
Timeframe: 8 weeks

InterventionParticipants (Count of Participants)
Sertraline58

[back to top]

Quality of Life -WHOQOL Intrument Scores

"QOL scores as measured by World Heath Organization Quality of Life - WHOQOL -BREF instrument.~scores 0-20 . Higher scores means a better outcome. The measure presented is a overall domain with the mean (SD)" (NCT02901249)
Timeframe: 12 weeks

Interventionscore on a scale (Mean)
Sertraline9.45

[back to top]

"Number of Participants With Response to Treatment"

"Response to treatment was defined as a 50% reduction from baseline scores in Hamilton Rating Scale for Depression (HRSD)and Young Mania Rating Scale (YMRS) scales HRSD was developed to evaluate and quantify depression.Its abbreviated version,. Scoring is based on the 17-item scale and scores of 0-7 are considered as being normal. The cutoff points are: 8-17 for mild depression,18-24 for moderate depression, and 25 or more for severe depression. The maximum score being 52 on the 17-point scale.~YMRS is is the most widely used assessment tool for manic symptoms. The scale consists of 11 items .The YMRS follows the style of the Hamilton Rating Scale for Depression (HAM-D) with each item given a severity rating. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/agressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Scores of YMRS > 20 generates indicate mania" (NCT02918097)
Timeframe: 8 weeks

InterventionParticipants (Count of Participants)
Lithium Carbonate65

[back to top]

Number of Participants With Remission to Treatment

The remission outcome was established as obtaining three consecutive visits with scores of values considered asymptomatic Hamilton Rating Scale for Depression(HRSD <7 points) and Young Mania Rating Scale (YMRS <6 points) during the trial. The subjects that were asymptomatic for at least 6-8 month were considered to be in partial remission and complete if at least 12 months without symptoms, according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). (NCT02918097)
Timeframe: 8 months

InterventionParticipants (Count of Participants)
Lithium Carbonate21

[back to top]

Quality of Life Instrument Scores

"Quality of Life - WHOQOL -BREF instrument scores~scores 0-20 . higher scores mean a better outcome." (NCT02918097)
Timeframe: 12 weeks

Interventionscore on a scale (Mean)
Lithium Carbonate10.58

[back to top]

Number of Participants With Remission From Depression

Remission defined as Montgomery Asberg Depression Rating Scale score ≤10. Scale ranges from 0-60 with higher scores indicating higher depressive symptoms. (NCT02960763)
Timeframe: Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks

InterventionParticipants (Count of Participants)
Aripiprazole Augmentation61
Bupropion Augmentation58
Switch to Bupropion39
Lithium Augmentation24
Switch to Nortriptyline26

[back to top]

Serious Adverse Events

Life threatening illness, hospitalization, or need of medical care. (NCT02960763)
Timeframe: Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks

InterventionParticipants (Count of Participants)
Aripiprazole Augmentation15
Bupropion Augmentation15
Switch to Bupropion19
Lithium Augmentation12
Switch to Nortriptyline11

[back to top]

Psychological Well-Being

Psychological well-being was assessed using the NIH Toolbox Psychological Wellbeing subscales of Positive Affect and General Life Satisfaction, with a T score calculated as the average of these two subscales. Higher scores indicate greater positive affect and life satisfaction. Reference T-score (mean=50, SD=10). (NCT02960763)
Timeframe: Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks

,,,,
Interventiont-score (Mean)
baseline10 weeks
Aripiprazole Augmentation34.738.8
Bupropion Augmentation35.038.7
Lithium Augmentation33.135.7
Switch to Bupropion34.836.1
Switch to Nortriptyline34.235.6

[back to top]